20-F 1 glpg-20201231.htm 20-F glpg-20201231.htm
Large Accelerated Filer --12-31 FY false false 0001421876 BE false true false false BE 1 1 1 1 1 1 C9 false 4 4 one 0 1975 2023 2050 0001421876 glpg:InitialWarrantBIssuanceLiabilityMember glpg:GileadSciencesIncMember 2019-12-31 0001421876 glpg:SubsequentWarrantBIssuanceLiabilityMember glpg:GileadSciencesIncMember 2019-12-31 0001421876 ifrs-full:AssociatesMember glpg:FilgotinibDrugLicenseMember 2019-12-31 0001421876 glpg:November62019ExerciseOfWarrantsMember glpg:GileadMember 2019-01-01 2019-12-31 0001421876 glpg:GileadMember ifrs-full:TopOfRangeMember glpg:WarrantBMember 2019-10-22 2019-10-22 0001421876 glpg:GileadMember ifrs-full:BottomOfRangeMember glpg:WarrantBMember 2019-10-22 2019-10-22 0001421876 glpg:August232019ShareSubscriptionMember glpg:GileadMember 2019-01-01 2019-12-31 0001421876 glpg:GileadMember country:US 2018-01-01 2018-12-31 0001421876 glpg:GileadMember country:US 2019-01-01 2019-12-31 0001421876 glpg:GileadMember country:US 2020-01-01 2020-12-31 0001421876 glpg:FairValueReMeasurementOfFinancialInstrumentRelatedToIssuanceOfWarrantMember glpg:WarrantAMember 2019-01-01 2019-12-31 0001421876 glpg:FairValueReMeasurementOfFinancialInstrumentRelatedToIssuanceOfWarrantMember glpg:WarrantAMember 2020-01-01 2020-12-31 0001421876 glpg:FilgotinibDrugLicenseMember 2019-01-01 2019-12-31 0001421876 glpg:FilgotinibDrugLicenseMember 2020-01-01 2020-12-31 0001421876 glpg:GrantsMember 2020-12-31 0001421876 country:US 2018-01-01 2018-12-31 0001421876 country:US 2019-01-01 2019-12-31 0001421876 country:US 2020-01-01 2020-12-31 0001421876 glpg:GileadSciencesIncMember glpg:SecondCollaborationAgreementForFilgotinibMember 2020-12-15 0001421876 ifrs-full:AllOtherSegmentsMember ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2019-01-01 2019-12-31 0001421876 2019-01-01 0001421876 glpg:InnovationIncomeDeductionDividendReceivedDeductionAndInvestmentDeductionMember 2018-12-31 0001421876 glpg:InnovationIncomeDeductionDividendReceivedDeductionAndInvestmentDeductionMember 2019-12-31 0001421876 ifrs-full:AllOtherSegmentsMember ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2020-01-01 2020-12-31 0001421876 glpg:LandAndLeaseholdImprovementsMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2020-12-31 0001421876 glpg:InnovationIncomeDeductionDividendReceivedDeductionAndInvestmentDeductionMember 2020-12-31 0001421876 glpg:LandAndLeaseholdImprovementsMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2020-01-01 2020-12-31 0001421876 glpg:LandAndLeaseholdImprovementsMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2019-12-31 0001421876 glpg:LandAndLeaseholdImprovementsMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2019-01-01 2019-12-31 0001421876 glpg:LandAndLeaseholdImprovementsMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2018-12-31 0001421876 glpg:GileadMember 2019-08-22 2019-08-22 0001421876 glpg:LandAndLeaseholdImprovementsMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2018-01-01 2018-12-31 0001421876 glpg:LandAndLeaseholdImprovementsMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2017-12-31 0001421876 glpg:GileadMember 2019-08-23 2019-08-23 0001421876 glpg:OtherNonCurrentAssetsMember 2018-12-31 0001421876 glpg:LandAndLeaseholdImprovementsMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001421876 glpg:OtherNonCurrentAssetsMember 2019-12-31 0001421876 glpg:TradeLiabilitiesMember 2018-12-31 0001421876 glpg:TradeLiabilitiesMember 2019-12-31 0001421876 glpg:TradeLiabilitiesMember 2020-12-31 0001421876 glpg:OtherNonCurrentAssetsMember 2020-12-31 0001421876 glpg:SupervisoryBoardMembersAsGroupMember 2018-01-01 2018-12-31 0001421876 glpg:SupervisoryBoardMembersAsGroupMember 2019-01-01 2019-12-31 0001421876 ifrs-full:DisposalGroupsClassifiedAsHeldForSaleMember 2021-01-04 0001421876 glpg:LandAndLeaseholdImprovementsMember 2020-12-31 0001421876 glpg:LandAndLeaseholdImprovementsMember 2019-12-31 0001421876 2017-01-01 2017-12-31 0001421876 glpg:LandAndLeaseholdImprovementsMember ifrs-full:GrossCarryingAmountMember 2020-01-01 2020-12-31 0001421876 glpg:LandAndLeaseholdImprovementsMember 2018-12-31 0001421876 glpg:LandAndLeaseholdImprovementsMember ifrs-full:GrossCarryingAmountMember 2019-12-31 0001421876 glpg:LandAndLeaseholdImprovementsMember ifrs-full:GrossCarryingAmountMember 2019-01-01 2019-12-31 0001421876 glpg:LandAndLeaseholdImprovementsMember ifrs-full:GrossCarryingAmountMember 2018-12-31 0001421876 glpg:LandAndLeaseholdImprovementsMember ifrs-full:GrossCarryingAmountMember 2018-01-01 2018-12-31 0001421876 glpg:LandAndLeaseholdImprovementsMember ifrs-full:GrossCarryingAmountMember 2017-12-31 0001421876 glpg:GileadSciencesIncMember glpg:CollaborationAgreementForFilgotinibMember 2019-01-01 2019-12-31 0001421876 glpg:GileadCollaborationAgreementForZiritaxestatMember glpg:OptionLicenseAndCollaborationAgreementJuly142019Member 2019-07-14 0001421876 glpg:GileadSciencesIncMember glpg:CollaborationAgreementForFilgotinibMember 2020-01-01 2020-12-31 0001421876 glpg:SubsequentWarrantBIssuanceLiabilityMember glpg:OtherMovementsIn2020Member 2020-12-31 0001421876 glpg:MembersOfBoardOfDirectorsMember glpg:ExerciseOfWarrantsMember 2021-03-19 2021-03-19 0001421876 glpg:MembersOfExecutiveCommitteeMember glpg:ExerciseOfWarrantsMember 2021-03-19 2021-03-19 0001421876 glpg:FilgotinibAmendmentDecember152020Member 2020-12-15 0001421876 glpg:FilgotinibAmendmentDecember152020Member 2020-12-14 2020-12-15 0001421876 glpg:OptionLicenseAndCollaborationAgreementJuly142019Member 2019-07-14 0001421876 glpg:OptionLicenseAndCollaborationAgreementJuly142019Member 2019-07-13 2019-07-14 0001421876 glpg:MilestonesAchievedDuring2015To2019Member 2019-12-31 0001421876 glpg:MilestonesAchievedDuring2015To2019Member 2019-01-01 2019-12-31 0001421876 glpg:FilgotinibAgreement2015Member 2019-12-31 0001421876 glpg:FilgotinibAgreement2015Member 2019-01-01 2019-12-31 0001421876 glpg:OtherMovementsIn2020Member 2020-12-31 0001421876 glpg:OtherMovementsIn2020Member 2020-01-01 2020-12-31 0001421876 glpg:CeoMember glpg:ExerciseOfWarrantsMember 2021-03-19 2021-03-19 0001421876 glpg:FilgotinibDrugLicenseMember ifrs-full:TopOfRangeMember ifrs-full:ForeignCountriesMember 2019-07-14 2019-07-14 0001421876 glpg:FilgotinibDrugLicenseMember ifrs-full:BottomOfRangeMember ifrs-full:ForeignCountriesMember 2019-07-14 2019-07-14 0001421876 glpg:CollaborationAgreementForDrugDiscoveryPlatformMember glpg:GileadSciencesIncMember 2020-12-31 0001421876 glpg:InitialWarrantBIssuanceLiabilityMember glpg:GileadSciencesIncMember 2020-12-31 0001421876 glpg:WarrantAIssuanceLiabilityMember glpg:GileadSciencesIncMember 2020-12-31 0001421876 glpg:RestrictedStockUnitPlan2019IIIMember glpg:ShareBasedCompensationAwardVestingPercentagePortionTwoMember 2020-01-01 2020-12-31 0001421876 glpg:RestrictedStockUnitPlan2019IIIMember glpg:ShareBasedCompensationAwardVestingPercentagePortionOneMember 2020-01-01 2020-12-31 0001421876 glpg:RestrictedStockUnitPlan2019IIIMember glpg:IfrsShareBasedCompensationAwardTrancheTwoMember 2020-01-01 2020-12-31 0001421876 glpg:RestrictedStockUnitPlan2019IIIMember glpg:IfrsShareBasedCompensationAwardTrancheOneMember 2020-01-01 2020-12-31 0001421876 glpg:IfrsRestrictedStockUnitsRsusMember glpg:OtherMember 2019-12-31 0001421876 glpg:ManagementBoardMembersMember glpg:IfrsRestrictedStockUnitsRsusMember 2019-12-31 0001421876 glpg:ManagementBoardMembersMember glpg:IfrsRestrictedStockUnitsRsusMember 2020-12-31 0001421876 glpg:IfrsRestrictedStockUnitsRsusMember glpg:OtherMember 2020-12-31 0001421876 glpg:SubscriptionRightsMember glpg:SupervisoryBoardMembersMember 2020-01-01 2020-12-31 0001421876 ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:EquityInvestmentsMember 2020-12-31 0001421876 ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:EquityInvestmentsMember 2018-01-01 2018-12-31 0001421876 ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:EquityInvestmentsMember 2019-01-01 2019-12-31 0001421876 ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:EquityInvestmentsMember 2020-01-01 2020-12-31 0001421876 ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:EquityInvestmentsMember 2017-12-31 0001421876 ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:EquityInvestmentsMember 2018-12-31 0001421876 ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:EquityInvestmentsMember 2019-12-31 0001421876 glpg:GileadMember glpg:FilgotinibDrugLicenseMember 2020-01-01 2020-12-31 0001421876 glpg:GileadMember ifrs-full:TopOfRangeMember glpg:FilgotinibDrugLicenseMember 2020-01-01 2020-12-31 0001421876 glpg:GileadMember ifrs-full:BottomOfRangeMember glpg:FilgotinibDrugLicenseMember 2020-01-01 2020-12-31 0001421876 glpg:GileadMember glpg:FilgotinibDrugLicenseMember 2020-12-31 0001421876 glpg:GileadMember ifrs-full:BottomOfRangeMember 2019-07-14 0001421876 glpg:GileadSciencesIncMember glpg:SubsequentWarrantBIssuanceLiabilityMember 2020-12-31 0001421876 glpg:MicheleMantoMember glpg:IfrsRestrictedStockUnitsRsusMember 2018-01-01 2018-12-31 0001421876 glpg:WalidAbiSaabMember glpg:IfrsRestrictedStockUnitsRsusMember 2018-01-01 2018-12-31 0001421876 glpg:PietWigerinkMember glpg:IfrsRestrictedStockUnitsRsusMember 2018-01-01 2018-12-31 0001421876 glpg:AndreHoekemaMember glpg:IfrsRestrictedStockUnitsRsusMember 2018-01-01 2018-12-31 0001421876 glpg:BartFilusMember glpg:IfrsRestrictedStockUnitsRsusMember 2018-01-01 2018-12-31 0001421876 glpg:OnnoVanDeStolpeMember glpg:IfrsRestrictedStockUnitsRsusMember 2018-01-01 2018-12-31 0001421876 glpg:MicheleMantoMember glpg:IfrsRestrictedStockUnitsRsusMember 2019-01-01 2019-12-31 0001421876 glpg:WalidAbiSaabMember glpg:IfrsRestrictedStockUnitsRsusMember 2019-01-01 2019-12-31 0001421876 glpg:PietWigerinkMember glpg:IfrsRestrictedStockUnitsRsusMember 2019-01-01 2019-12-31 0001421876 glpg:AndreHoekemaMember glpg:IfrsRestrictedStockUnitsRsusMember 2019-01-01 2019-12-31 0001421876 glpg:BartFilusMember glpg:IfrsRestrictedStockUnitsRsusMember 2019-01-01 2019-12-31 0001421876 glpg:OnnoVanDeStolpeMember glpg:IfrsRestrictedStockUnitsRsusMember 2019-01-01 2019-12-31 0001421876 glpg:MicheleMantoMember glpg:IfrsRestrictedStockUnitsRsusMember 2020-01-01 2020-12-31 0001421876 glpg:WalidAbiSaabMember glpg:IfrsRestrictedStockUnitsRsusMember 2020-01-01 2020-12-31 0001421876 glpg:PietWigerinkMember glpg:IfrsRestrictedStockUnitsRsusMember 2020-01-01 2020-12-31 0001421876 glpg:AndreHoekemaMember glpg:IfrsRestrictedStockUnitsRsusMember 2020-01-01 2020-12-31 0001421876 glpg:BartFilusMember glpg:IfrsRestrictedStockUnitsRsusMember 2020-01-01 2020-12-31 0001421876 glpg:OnnoVanDeStolpeMember glpg:IfrsRestrictedStockUnitsRsusMember 2020-01-01 2020-12-31 0001421876 glpg:PeterGuenterMember glpg:WarrantsMember 2019-01-01 2019-12-31 0001421876 glpg:MaryKerrMember glpg:WarrantsMember 2018-01-01 2018-12-31 0001421876 glpg:MaryKerrMember glpg:WarrantsMember 2019-01-01 2019-12-31 0001421876 glpg:ChristineMummeryMember glpg:WarrantsMember 2018-01-01 2018-12-31 0001421876 glpg:KatrineBosleyMember glpg:WarrantsMember 2018-01-01 2018-12-31 0001421876 glpg:KatrineBosleyMember glpg:WarrantsMember 2019-01-01 2019-12-31 0001421876 glpg:WernerCautreelsMember glpg:WarrantsMember 2018-01-01 2018-12-31 0001421876 glpg:OtherCountriesMember 2018-12-31 0001421876 glpg:OtherCountriesMember 2019-12-31 0001421876 glpg:OtherCountriesMember 2020-12-31 0001421876 glpg:HowardRoweMember glpg:WarrantsMember 2018-01-01 2018-12-31 0001421876 glpg:CollaborationAgreementForFilgotinibMember 2020-12-31 0001421876 ifrs-full:DisposalGroupsClassifiedAsHeldForSaleMember 2020-01-01 2020-12-31 0001421876 glpg:HowardRoweMember glpg:WarrantsMember 2019-01-01 2019-12-31 0001421876 glpg:RajParekhMember glpg:WarrantsMember 2018-01-01 2018-12-31 0001421876 glpg:ExerciseOfWarrantsMember 2021-03-19 0001421876 glpg:RajParekhMember glpg:WarrantsMember 2019-01-01 2019-12-31 0001421876 glpg:MicheleMantoMember glpg:WarrantsMember 2019-01-01 2019-12-31 0001421876 glpg:ExerciseOfWarrantsMember 2021-03-19 2021-03-19 0001421876 glpg:GileadSciencesIncMember 2020-12-31 0001421876 glpg:SubscriptionRightPlan2020RmvAllocatedOnApril2020Member 2020-01-01 2020-12-31 0001421876 glpg:SubscriptionRightPlan2020RmvAllocatedOnApril2020Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2020AllocatedOnApril2020Member 2020-01-01 2020-12-31 0001421876 glpg:SubscriptionRightPlan2020AllocatedOnApril2020Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2019RmvAllocatedOnApril2019Member 2020-01-01 2020-12-31 0001421876 glpg:SubscriptionRightPlan2019RmvAllocatedOnApril2019Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2019RmvAllocatedOnApril2019Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2019AllocatedOnApril2019Member 2020-01-01 2020-12-31 0001421876 glpg:SubscriptionRightPlan2019AllocatedOnApril2019Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2019AllocatedOnApril2019Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2018RmvAllocatedOnApril2018Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2018RmvAllocatedOnApril2018Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2018AllocatedOnApril2018Member 2020-01-01 2020-12-31 0001421876 glpg:SubscriptionRightPlan2018AllocatedOnApril2018Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2018AllocatedOnApril2018Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2017RmvAllocatedOnMay2017Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2017RmvAllocatedOnMay2017Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2017AllocatedOnMay2017Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2017AllocatedOnMay2017Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2016BAllocatedOnJanuary2017Member 2020-01-01 2020-12-31 0001421876 glpg:SubscriptionRightPlan2016BAllocatedOnJanuary2017Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2016BAllocatedOnJanuary2017Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2016RmvAllocatedOnJune2016Member 2020-01-01 2020-12-31 0001421876 glpg:SubscriptionRightPlan2016RmvAllocatedOnJune2016Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2016RmvAllocatedOnJune2016Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2016AllocatedOnJune2016Member 2020-01-01 2020-12-31 0001421876 glpg:SubscriptionRightPlan2016AllocatedOnJune2016Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2016AllocatedOnJune2016Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2015RmvAllocatedOnDecember2015Member 2020-01-01 2020-12-31 0001421876 glpg:SubscriptionRightPlan2015RmvAllocatedOnDecember2015Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2015RmvAllocatedOnDecember2015Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2015BAllocatedOnDecember2015Member 2020-01-01 2020-12-31 0001421876 glpg:SubscriptionRightPlan2015BAllocatedOnDecember2015Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2015BAllocatedOnDecember2015Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2015AllocatedOnApril2015Member 2020-01-01 2020-12-31 0001421876 glpg:SubscriptionRightPlan2015AllocatedOnApril2015Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2015AllocatedOnApril2015Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2014AllocatedOnJuly2014Member 2020-01-01 2020-12-31 0001421876 glpg:SubscriptionRightPlan2014AllocatedOnJuly2014Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2014AllocatedOnJuly2014Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2013AllocatedOnMay2013Member 2020-01-01 2020-12-31 0001421876 glpg:SubscriptionRightPlan2013AllocatedOnMay2013Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2013AllocatedOnMay2013Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2012AllocatedOnSeptember2012Member 2020-01-01 2020-12-31 0001421876 glpg:SubscriptionRightPlan2012AllocatedOnSeptember2012Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2012AllocatedOnSeptember2012Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2008AllocatedOnJune2008Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2008AllocatedOnJune2008Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2007RmvAllocatedOnOctober2007Member 2020-01-01 2020-12-31 0001421876 glpg:SubscriptionRightPlan2007RmvAllocatedOnOctober2007Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2007RmvAllocatedOnOctober2007Member 2020-12-31 0001421876 glpg:SubscriptionRightPlan2006BnlAllocatedOnDecember2007Member 2020-01-01 2020-12-31 0001421876 glpg:SubscriptionRightPlan2006BnlAllocatedOnDecember2007Member 2019-12-31 0001421876 glpg:SubscriptionRightPlan2006BnlAllocatedOnDecember2007Member 2020-12-31 0001421876 glpg:RestrictedStockUnitPlan2019IMember 2020-01-01 2020-12-31 0001421876 glpg:IfrsRestrictedStockUnitsRsusMember 2018-12-31 0001421876 glpg:IfrsRestrictedStockUnitsRsusMember 2020-12-31 0001421876 glpg:IfrsRestrictedStockUnitsRsusMember 2019-12-31 0001421876 glpg:RestrictedStockUnitPlan2020IIMember 2020-12-31 0001421876 glpg:RestrictedStockUnitPlan2020IIMember 2020-01-01 2020-12-31 0001421876 glpg:RestrictedStockUnitPlan2020IMember 2020-12-31 0001421876 glpg:RestrictedStockUnitPlan2020IMember 2020-01-01 2020-12-31 0001421876 glpg:RestrictedStockUnitPlan2019IIIMember 2020-12-31 0001421876 glpg:RestrictedStockUnitPlan2019IIIMember 2019-12-31 0001421876 glpg:RestrictedStockUnitPlan2019IIMember 2020-12-31 0001421876 glpg:RestrictedStockUnitPlan2019IIMember 2020-01-01 2020-12-31 0001421876 glpg:RestrictedStockUnitPlan2019IIMember 2019-12-31 0001421876 glpg:RestrictedStockUnitPlan2019IMember 2020-12-31 0001421876 glpg:RestrictedStockUnitPlan2019IMember 2019-12-31 0001421876 glpg:SubscriptionRightsMember 2018-12-31 0001421876 glpg:SubscriptionRightsMember 2019-12-31 0001421876 glpg:SubscriptionRightsMember 2020-12-31 0001421876 glpg:SubscriptionRightsMember 2018-01-01 2018-12-31 0001421876 glpg:SubscriptionRightsMember 2019-01-01 2019-12-31 0001421876 glpg:SubscriptionRightsMember 2020-01-01 2020-12-31 0001421876 ifrs-full:EquityInvestmentsMember 2020-12-31 0001421876 ifrs-full:EquityInvestmentsMember 2018-01-01 2018-12-31 0001421876 ifrs-full:EquityInvestmentsMember 2019-01-01 2019-12-31 0001421876 ifrs-full:EquityInvestmentsMember 2020-01-01 2020-12-31 0001421876 ifrs-full:EquityInvestmentsMember 2017-12-31 0001421876 ifrs-full:EquityInvestmentsMember 2018-12-31 0001421876 ifrs-full:EquityInvestmentsMember 2019-12-31 0001421876 ifrs-full:LeaseLiabilitiesMember 2018-12-31 0001421876 glpg:CurrentFinancialInstrumentsLiabilitiesMember 2018-12-31 0001421876 glpg:CurrentFinancialInvestmentsMember 2018-12-31 0001421876 ifrs-full:EquityInvestmentsMember 2018-12-31 0001421876 ifrs-full:EquityInvestmentsMember 2019-12-31 0001421876 2019-07-14 2019-07-14 0001421876 glpg:MicheleMantoMember glpg:WarrantsMember 2020-01-01 2020-12-31 0001421876 glpg:WalidAbiSaabMember glpg:WarrantsMember 2019-01-01 2019-12-31 0001421876 glpg:WalidAbiSaabMember glpg:WarrantsMember 2020-01-01 2020-12-31 0001421876 glpg:PietWigerinkMember glpg:WarrantsMember 2019-01-01 2019-12-31 0001421876 2017-12-31 0001421876 ifrs-full:EquityInvestmentsMember 2020-12-31 0001421876 glpg:GileadMember 2019-07-14 0001421876 ifrs-full:DisposalGroupsClassifiedAsHeldForSaleMember 2020-12-31 0001421876 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2020-01-01 2020-12-31 0001421876 country:ES 2018-12-31 0001421876 country:ES 2019-12-31 0001421876 country:ES 2020-12-31 0001421876 country:HR 2020-12-31 0001421876 glpg:IfrsRestrictedStockUnitsRsusMember 2018-01-01 2018-12-31 0001421876 glpg:PietWigerinkMember glpg:WarrantsMember 2020-01-01 2020-12-31 0001421876 glpg:AndreHoekemaMember glpg:WarrantsMember 2019-01-01 2019-12-31 0001421876 glpg:AndreHoekemaMember glpg:WarrantsMember 2020-01-01 2020-12-31 0001421876 glpg:BartFilusMember glpg:WarrantsMember 2019-01-01 2019-12-31 0001421876 glpg:BartFilusMember glpg:WarrantsMember 2020-01-01 2020-12-31 0001421876 glpg:OnnoVanDeStolpeMember glpg:WarrantsMember 2019-01-01 2019-12-31 0001421876 glpg:OnnoVanDeStolpeMember glpg:WarrantsMember 2020-01-01 2020-12-31 0001421876 glpg:ExecutiveCommitteeMembersAsGroupMember glpg:WarrantsMember 2018-01-01 2018-12-31 0001421876 glpg:ExecutiveCommitteeMembersAsGroupMember glpg:WarrantsMember 2019-01-01 2019-12-31 0001421876 glpg:ExecutiveCommitteeMembersAsGroupMember glpg:WarrantsMember 2020-01-01 2020-12-31 0001421876 ifrs-full:AssociatesMember glpg:GileadCollaborationAgreementForDrugDiscoveryPlatformMember 2020-12-31 0001421876 ifrs-full:AssociatesMember glpg:EuropeanAuthoritiesMember 2020-09-25 2020-09-25 0001421876 ifrs-full:AssociatesMember glpg:JapaneseAuthoritiesMember 2020-09-25 2020-09-25 0001421876 ifrs-full:AssociatesMember glpg:CollaborationAgreementForFilgotinibMember 2020-12-31 0001421876 glpg:ExecutiveCommitteeMembersAsGroupMember 2020-01-01 2020-12-31 0001421876 glpg:ElisabethSvanbergMember 2020-01-01 2020-12-31 0001421876 glpg:PeterGuenterMember 2020-01-01 2020-12-31 0001421876 glpg:MaryKerrMember 2020-01-01 2020-12-31 0001421876 glpg:GileadMember glpg:FilgotinibDrugLicenseMember glpg:GroupBActivitiesMember 2020-12-31 0001421876 glpg:KatrineBosleyMember 2020-01-01 2020-12-31 0001421876 glpg:HowardRoweMember 2020-01-01 2020-12-31 0001421876 glpg:RajParekhMember 2020-01-01 2020-12-31 0001421876 glpg:GileadCollaborationAgreementForZiritaxestatAndFilgotinibMember 2020-12-31 0001421876 glpg:FilgotinibDrugLicenseMember 2020-12-01 2020-12-31 0001421876 glpg:OtherDeferredIncomeMember 2020-01-01 2020-12-31 0001421876 ifrs-full:LaterThanFiveYearsMember 2020-12-31 0001421876 ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member 2019-01-01 2019-12-31 0001421876 glpg:GileadMember 2020-01-01 2020-12-31 0001421876 glpg:GileadCollaborationAgreementForDrugDiscoveryPlatformMember glpg:GileadSciencesIncMember 2020-01-01 2020-12-31 0001421876 glpg:FilgotinibDrugLicenseMember glpg:GileadSciencesIncMember 2020-09-01 2020-09-30 0001421876 ifrs-full:DiscontinuedOperationsMember 2020-12-31 0001421876 ifrs-full:DiscontinuedOperationsMember 2018-01-01 2018-12-31 0001421876 ifrs-full:DiscontinuedOperationsMember 2019-01-01 2019-12-31 0001421876 ifrs-full:DiscontinuedOperationsMember 2020-01-01 2020-12-31 0001421876 glpg:CollaborationAgreementForMor106Member glpg:NovartisMember ifrs-full:GoodsOrServicesTransferredOverTimeMember 2020-01-01 2020-12-31 0001421876 glpg:CollaborationAgreementForCfMember glpg:AbbvieMember ifrs-full:GoodsOrServicesTransferredOverTimeMember 2020-01-01 2020-12-31 0001421876 glpg:MajorCustomersOfEntityMember 2018-01-01 2018-12-31 0001421876 glpg:MajorCustomersOfEntityMember 2019-01-01 2019-12-31 0001421876 glpg:MajorCustomersOfEntityMember 2020-01-01 2020-12-31 0001421876 2018-01-01 2018-12-31 0001421876 2018-12-31 0001421876 2019-12-31 0001421876 ifrs-full:LaterThanThreeMonthsAndNotLaterThanFourMonthsMember ifrs-full:TradeReceivablesMember ifrs-full:CreditRiskMember 2019-12-31 0001421876 glpg:OtherMovementsIn2020Member glpg:CollaborationAgreementForDrugDiscoveryPlatformMember 2020-12-31 0001421876 glpg:WarrantAIssuanceLiabilityMember glpg:GileadSciencesIncMember 2019-12-31 0001421876 glpg:OptionLicenseAndCollaborationAgreementJuly142019Member glpg:CollaborationAgreementForDrugDiscoveryPlatformMember 2019-07-14 0001421876 glpg:GileadSciencesIncMember ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember glpg:CollaborationAgreementForFilgotinibMember 2018-01-01 2018-12-31 0001421876 2020-12-31 0001421876 glpg:AbbvieMember ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember glpg:CollaborationAgreementForCfMember 2018-01-01 2018-12-31 0001421876 2019-01-01 2019-12-31 0001421876 glpg:November62019ExerciseOfWarrantsMember ifrs-full:IssuedCapitalMember glpg:GileadMember 2019-01-01 2019-12-31 0001421876 glpg:November62019ExerciseOfWarrantsMember glpg:ShareCapitalAndSharePremiumMember glpg:GileadMember 2019-01-01 2019-12-31 0001421876 glpg:GileadCollaborationAgreementForDrugDiscoveryPlatformMember glpg:GileadSciencesIncMember ifrs-full:GoodsOrServicesTransferredOverTimeMember 2020-01-01 2020-12-31 0001421876 glpg:CollaborationAgreementForFilgotinibMember glpg:GileadSciencesIncMember ifrs-full:GoodsOrServicesTransferredOverTimeMember 2020-01-01 2020-12-31 0001421876 ifrs-full:AllOtherSegmentsMember ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member 2019-01-01 2019-12-31 0001421876 glpg:ZiritaxestatProgramMember 2018-01-01 2018-12-31 0001421876 glpg:ZiritaxestatProgramMember 2019-01-01 2019-12-31 0001421876 glpg:ZiritaxestatProgramMember 2020-01-01 2020-12-31 0001421876 dei:BusinessContactMember 2020-01-01 2020-12-31 0001421876 ifrs-full:InAccordanceWithIFRS9Member 2017-12-31 0001421876 ifrs-full:AggregateContinuingAndDiscontinuedOperationsMember 2018-12-31 0001421876 ifrs-full:AggregateContinuingAndDiscontinuedOperationsMember 2019-12-31 0001421876 country:HR 2018-12-31 0001421876 country:HR 2019-12-31 0001421876 ifrs-full:AssociatesMember 2019-08-28 2019-08-28 0001421876 glpg:NovartisMember 2018-07-01 2018-07-31 0001421876 glpg:WarrantsPlan2020RmvAllocatedOnApril2020Member 2020-01-01 2020-12-31 0001421876 glpg:WarrantsPlan2020AllocatedOnApril2020Member 2020-01-01 2020-12-31 0001421876 ifrs-full:DisposalGroupsClassifiedAsHeldForSaleMember 2021-01-03 2021-01-04 0001421876 glpg:OtherDeferredIncomeMember ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member 2017-12-31 0001421876 glpg:FeeForServicesSegmentMember ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member 2017-12-31 0001421876 glpg:SubsequentWarrantBMember 2019-12-31 0001421876 glpg:GileadCollaborationAgreementForZiritaxestatMember glpg:GileadSciencesIncMember 2019-01-01 2019-12-31 0001421876 glpg:SubsequentWarrantBMember 2020-12-31 0001421876 glpg:GileadMember glpg:NorthAmericaAndEuropeMember 2019-01-01 2019-12-31 0001421876 srt:EuropeMember glpg:NovartisMember 2018-01-01 2018-12-31 0001421876 srt:EuropeMember glpg:NovartisMember 2019-01-01 2019-12-31 0001421876 srt:EuropeMember glpg:NovartisMember 2020-01-01 2020-12-31 0001421876 glpg:AbbvieCustomerMember srt:EuropeMember 2018-01-01 2018-12-31 0001421876 glpg:AbbvieCustomerMember srt:EuropeMember 2019-01-01 2019-12-31 0001421876 glpg:AbbvieCustomerMember srt:EuropeMember 2020-01-01 2020-12-31 0001421876 glpg:December42020ExerciseOfWarrantsMember glpg:ShareCapitalAndSharePremiumMember 2020-01-01 2020-12-31 0001421876 glpg:September182020ExerciseOfWarrantsMember glpg:ShareCapitalAndSharePremiumMember 2020-01-01 2020-12-31 0001421876 glpg:May282020ExerciseOfWarrantsMember glpg:ShareCapitalAndSharePremiumMember 2020-01-01 2020-12-31 0001421876 glpg:GileadCollaborationAgreementForDrugDiscoveryPlatformMember 2020-12-31 0001421876 glpg:GileadSciencesIncMember 2019-01-01 2019-12-31 0001421876 ifrs-full:TopOfRangeMember 2017-04-24 2017-04-25 0001421876 ifrs-full:BottomOfRangeMember 2017-04-24 2017-04-25 0001421876 glpg:March172020ExerciseOfWarrantsMember glpg:ShareCapitalAndSharePremiumMember 2020-01-01 2020-12-31 0001421876 glpg:December42020ExerciseOfWarrantsMember ifrs-full:SharePremiumMember 2020-01-01 2020-12-31 0001421876 glpg:September182020ExerciseOfWarrantsMember ifrs-full:SharePremiumMember 2020-01-01 2020-12-31 0001421876 glpg:SpecificAuthorizationOfShareCapitalMember 2017-04-24 2017-04-25 0001421876 glpg:SpecificAuthorizationOfShareCapitalMember 2017-04-25 0001421876 glpg:GeneralAuthorizationOfShareCapitalMember 2019-10-22 0001421876 glpg:GeneralAuthorizationOfShareCapitalMember 2019-10-21 2019-10-22 0001421876 glpg:May282020ExerciseOfWarrantsMember ifrs-full:SharePremiumMember 2020-01-01 2020-12-31 0001421876 glpg:March172020ExerciseOfWarrantsMember ifrs-full:SharePremiumMember 2020-01-01 2020-12-31 0001421876 glpg:OrdinarySharesNoClassMember 2020-12-31 0001421876 glpg:December42020ExerciseOfWarrantsMember 2020-01-01 2020-12-31 0001421876 glpg:September182020ExerciseOfWarrantsMember 2020-01-01 2020-12-31 0001421876 glpg:May282020ExerciseOfWarrantsMember 2020-01-01 2020-12-31 0001421876 glpg:December42020ExerciseOfWarrantsMember ifrs-full:IssuedCapitalMember 2020-01-01 2020-12-31 0001421876 glpg:September182020ExerciseOfWarrantsMember ifrs-full:IssuedCapitalMember 2020-01-01 2020-12-31 0001421876 glpg:May282020ExerciseOfWarrantsMember ifrs-full:IssuedCapitalMember 2020-01-01 2020-12-31 0001421876 glpg:March172020ExerciseOfWarrantsMember ifrs-full:IssuedCapitalMember 2020-01-01 2020-12-31 0001421876 glpg:November252019ExerciseOfWarrantsMember glpg:ShareCapitalAndSharePremiumMember 2019-01-01 2019-12-31 0001421876 glpg:November62019ExerciseOfWarrantsMember ifrs-full:SharePremiumMember glpg:GileadMember 2019-01-01 2019-12-31 0001421876 glpg:November62019ExerciseOfWarrantsMember glpg:WarrantsMember glpg:ShareCapitalAndSharePremiumMember glpg:GileadMember 2019-01-01 2019-12-31 0001421876 glpg:November62019ExerciseOfWarrantsMember glpg:WarrantsMember ifrs-full:SharePremiumMember glpg:GileadMember 2019-01-01 2019-12-31 0001421876 glpg:November62019ExerciseOfWarrantsMember glpg:WarrantsMember ifrs-full:IssuedCapitalMember glpg:GileadMember 2019-01-01 2019-12-31 0001421876 glpg:November252019ExerciseOfWarrantsMember ifrs-full:SharePremiumMember 2019-01-01 2019-12-31 0001421876 glpg:November62019ExerciseOfWarrantsMember glpg:WarrantsMember glpg:GileadMember 2019-01-01 2019-12-31 0001421876 glpg:August232019ShareSubscriptionMember ifrs-full:IssuedCapitalMember glpg:GileadMember 2019-01-01 2019-12-31 0001421876 glpg:November252019ExerciseOfWarrantsMember ifrs-full:IssuedCapitalMember 2019-01-01 2019-12-31 0001421876 glpg:September192019ExerciseOfWarrantsMember glpg:ShareCapitalAndSharePremiumMember 2019-01-01 2019-12-31 0001421876 glpg:March172020ExerciseOfWarrantsMember 2020-01-01 2020-12-31 0001421876 glpg:ShareCapitalAndSharePremiumMember 2019-12-31 0001421876 glpg:November252019ExerciseOfWarrantsMember 2019-01-01 2019-12-31 0001421876 glpg:September192019ExerciseOfWarrantsMember 2019-01-01 2019-12-31 0001421876 glpg:September192019ExerciseOfWarrantsMember ifrs-full:SharePremiumMember 2019-01-01 2019-12-31 0001421876 glpg:September192019ExerciseOfWarrantsMember ifrs-full:IssuedCapitalMember 2019-01-01 2019-12-31 0001421876 glpg:ShareCapitalAndSharePremiumMember 2018-12-31 0001421876 glpg:ShareCapitalAndSharePremiumMember 2017-12-31 0001421876 glpg:ShareCapitalAndSharePremiumMember glpg:AmericanDepositaryReceiptsMember 2018-01-01 2018-12-31 0001421876 ifrs-full:SharePremiumMember glpg:AmericanDepositaryReceiptsMember 2018-01-01 2018-12-31 0001421876 ifrs-full:IssuedCapitalMember glpg:AmericanDepositaryReceiptsMember 2018-01-01 2018-12-31 0001421876 glpg:CollaborationAgreementForOsteoarthritisMember glpg:ServierMember ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2018-01-01 2018-12-31 0001421876 glpg:CollaborationAgreementForMor106Member glpg:NovartisMember ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2018-01-01 2018-12-31 0001421876 glpg:CollaborationAgreementForCfMember glpg:AbbvieMember ifrs-full:GoodsOrServicesTransferredOverTimeMember 2018-01-01 2018-12-31 0001421876 glpg:CollaborationAgreementForFilgotinibMember glpg:GileadSciencesIncMember ifrs-full:GoodsOrServicesTransferredOverTimeMember 2018-01-01 2018-12-31 0001421876 glpg:June202019ExerciseOfWarrantsMember glpg:ShareCapitalAndSharePremiumMember 2019-01-01 2019-12-31 0001421876 ifrs-full:AllOtherSegmentsMember 2018-01-01 2018-12-31 0001421876 glpg:March202019ExerciseOfWarrantsMember glpg:ShareCapitalAndSharePremiumMember 2019-01-01 2019-12-31 0001421876 glpg:June202019ExerciseOfWarrantsMember ifrs-full:SharePremiumMember 2019-01-01 2019-12-31 0001421876 glpg:March202019ExerciseOfWarrantsMember ifrs-full:SharePremiumMember 2019-01-01 2019-12-31 0001421876 glpg:June202019ExerciseOfWarrantsMember ifrs-full:IssuedCapitalMember 2019-01-01 2019-12-31 0001421876 glpg:March202019ExerciseOfWarrantsMember ifrs-full:IssuedCapitalMember 2019-01-01 2019-12-31 0001421876 glpg:GileadCollaborationAgreementForDrugDiscoveryPlatformMember glpg:GileadSciencesIncMember ifrs-full:GoodsOrServicesTransferredOverTimeMember 2019-01-01 2019-12-31 0001421876 glpg:November232018ExerciseOfWarrantsMember glpg:ShareCapitalAndSharePremiumMember 2018-01-01 2018-12-31 0001421876 glpg:June202019ExerciseOfWarrantsMember 2019-01-01 2019-12-31 0001421876 glpg:October032018ExerciseOfWarrantsMember glpg:ShareCapitalAndSharePremiumMember 2018-01-01 2018-12-31 0001421876 glpg:November232018ExerciseOfWarrantsMember ifrs-full:SharePremiumMember 2018-01-01 2018-12-31 0001421876 glpg:October032018ExerciseOfWarrantsMember ifrs-full:SharePremiumMember 2018-01-01 2018-12-31 0001421876 glpg:November232018ExerciseOfWarrantsMember ifrs-full:IssuedCapitalMember 2018-01-01 2018-12-31 0001421876 glpg:October032018ExerciseOfWarrantsMember ifrs-full:IssuedCapitalMember 2018-01-01 2018-12-31 0001421876 glpg:CollaborationAgreementForMor106Member glpg:NovartisMember ifrs-full:GoodsOrServicesTransferredOverTimeMember 2019-01-01 2019-12-31 0001421876 glpg:CollaborationAgreementForCfMember glpg:AbbvieMember ifrs-full:GoodsOrServicesTransferredOverTimeMember 2019-01-01 2019-12-31 0001421876 glpg:CollaborationAgreementForFilgotinibMember glpg:GileadSciencesIncMember ifrs-full:GoodsOrServicesTransferredOverTimeMember 2019-01-01 2019-12-31 0001421876 glpg:U.s.PublicOfferingMember glpg:ShareCapitalAndSharePremiumMember 2018-01-01 2018-12-31 0001421876 glpg:U.s.PublicOfferingMember ifrs-full:SharePremiumMember 2018-01-01 2018-12-31 0001421876 glpg:March202019ExerciseOfWarrantsMember 2019-01-01 2019-12-31 0001421876 glpg:U.s.PublicOfferingMember ifrs-full:IssuedCapitalMember 2018-01-01 2018-12-31 0001421876 glpg:CollaborationAgreementForDrugDiscoveryPlatformMember glpg:GileadSciencesIncMember 2019-12-31 0001421876 glpg:November232018ExerciseOfWarrantsMember 2018-01-01 2018-12-31 0001421876 glpg:October032018ExerciseOfWarrantsMember 2018-01-01 2018-12-31 0001421876 glpg:ShareCapitalAndSharePremiumMember 2018-01-01 2018-12-31 0001421876 glpg:June202018ExerciseOfWarrantsMember glpg:ShareCapitalAndSharePremiumMember 2018-01-01 2018-12-31 0001421876 glpg:March202018ExerciseOfWarrantsMember glpg:ShareCapitalAndSharePremiumMember 2018-01-01 2018-12-31 0001421876 glpg:June202018ExerciseOfWarrantsMember ifrs-full:SharePremiumMember 2018-01-01 2018-12-31 0001421876 glpg:March202018ExerciseOfWarrantsMember ifrs-full:SharePremiumMember 2018-01-01 2018-12-31 0001421876 glpg:June202018ExerciseOfWarrantsMember ifrs-full:IssuedCapitalMember 2018-01-01 2018-12-31 0001421876 glpg:March202018ExerciseOfWarrantsMember ifrs-full:IssuedCapitalMember 2018-01-01 2018-12-31 0001421876 glpg:LesLaboratoiresServierMember srt:EuropeMember 2019-01-01 2019-12-31 0001421876 glpg:GileadSciencesIncMember 2019-12-31 0001421876 glpg:GileadMember srt:EuropeMember 2019-01-01 2019-12-31 0001421876 glpg:LesLaboratoiresServierMember srt:EuropeMember 2018-01-01 2018-12-31 0001421876 glpg:GileadMember srt:EuropeMember 2018-01-01 2018-12-31 0001421876 glpg:LesLaboratoiresServierMember srt:EuropeMember 2020-01-01 2020-12-31 0001421876 glpg:U.s.PublicOfferingMember 2018-01-01 2018-12-31 0001421876 glpg:AmericanDepositaryReceiptsMember 2018-01-01 2018-12-31 0001421876 glpg:GileadMember srt:EuropeMember 2020-01-01 2020-12-31 0001421876 glpg:June202018ExerciseOfWarrantsMember 2018-01-01 2018-12-31 0001421876 glpg:March202018ExerciseOfWarrantsMember 2018-01-01 2018-12-31 0001421876 country:BE ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember 2020-12-31 0001421876 glpg:ShareCapitalAndSharePremiumMember 2020-12-31 0001421876 country:BE ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2020-12-31 0001421876 country:CH 2018-12-31 0001421876 country:BE ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2020-12-31 0001421876 country:NL 2018-12-31 0001421876 country:FR ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2020-12-31 0001421876 country:BE ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2020-12-31 0001421876 country:FR 2018-12-31 0001421876 country:FR ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2020-12-31 0001421876 country:BE ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2020-12-31 0001421876 country:BE 2018-12-31 0001421876 country:FR ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2020-12-31 0001421876 country:CH 2019-12-31 0001421876 country:FR 2019-12-31 0001421876 country:CH 2020-12-31 0001421876 glpg:SharesIssuedOnDecember42020Member 2020-12-31 0001421876 glpg:SharesIssuedOnSeptember182020Member 2020-12-31 0001421876 glpg:SharesIssuedOnMay282020Member 2020-12-31 0001421876 glpg:SharesIssuedOnMarch172020Member 2020-12-31 0001421876 srt:EuropeMember 2018-01-01 2018-12-31 0001421876 glpg:SharesIssuedOnNovember252019Member 2019-12-31 0001421876 glpg:SharesIssuedOnNovember62019Member 2019-12-31 0001421876 glpg:SharesIssuedOnSeptember192019Member 2019-12-31 0001421876 glpg:SharesIssuedOnAugust232019Member 2019-12-31 0001421876 glpg:SharesIssuedOnJune202019Member 2019-12-31 0001421876 glpg:SharesIssuedOnMarch202019Member 2019-12-31 0001421876 glpg:SharesIssuedOnNovember232018Member 2018-12-31 0001421876 glpg:SharesIssuedOnOctober32018Member 2018-12-31 0001421876 glpg:SharesIssuedOnSeptember172018Member 2018-12-31 0001421876 glpg:SharesIssuedOnJune202018Member 2018-12-31 0001421876 glpg:SharesIssuedOnMarch202018Member 2018-12-31 0001421876 srt:EuropeMember 2019-01-01 2019-12-31 0001421876 srt:EuropeMember 2020-01-01 2020-12-31 0001421876 ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember 2020-12-31 0001421876 ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2020-12-31 0001421876 ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2020-12-31 0001421876 ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2020-12-31 0001421876 ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2020-12-31 0001421876 country:FR 2020-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember ifrs-full:ContractAssetsMember 2019-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember glpg:BrandsLicensesPatentsAndKnowHowMember 2019-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember ifrs-full:ComputerSoftwareMember 2019-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember ifrs-full:ContractAssetsMember 2019-01-01 2019-12-31 0001421876 ifrs-full:ContractAssetsMember 2019-12-31 0001421876 glpg:BrandsLicensesPatentsAndKnowHowMember 2019-12-31 0001421876 ifrs-full:ComputerSoftwareMember 2019-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember glpg:BrandsLicensesPatentsAndKnowHowMember 2019-01-01 2019-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember ifrs-full:ComputerSoftwareMember 2019-01-01 2019-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember 2019-12-31 0001421876 ifrs-full:GrossCarryingAmountMember ifrs-full:ContractAssetsMember 2019-12-31 0001421876 ifrs-full:GrossCarryingAmountMember glpg:BrandsLicensesPatentsAndKnowHowMember 2019-12-31 0001421876 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2019-12-31 0001421876 ifrs-full:GrossCarryingAmountMember ifrs-full:ContractAssetsMember 2019-01-01 2019-12-31 0001421876 ifrs-full:GrossCarryingAmountMember glpg:BrandsLicensesPatentsAndKnowHowMember 2019-01-01 2019-12-31 0001421876 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2019-01-01 2019-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember 2019-01-01 2019-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember ifrs-full:ContractAssetsMember 2018-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember glpg:BrandsLicensesPatentsAndKnowHowMember 2018-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember ifrs-full:ComputerSoftwareMember 2018-12-31 0001421876 ifrs-full:ContractAssetsMember 2018-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember glpg:BrandsLicensesPatentsAndKnowHowMember 2018-01-01 2018-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember ifrs-full:ComputerSoftwareMember 2018-01-01 2018-12-31 0001421876 glpg:BrandsLicensesPatentsAndKnowHowMember 2018-12-31 0001421876 ifrs-full:ComputerSoftwareMember 2018-12-31 0001421876 ifrs-full:GrossCarryingAmountMember ifrs-full:ContractAssetsMember 2018-12-31 0001421876 ifrs-full:GrossCarryingAmountMember glpg:BrandsLicensesPatentsAndKnowHowMember 2018-12-31 0001421876 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2018-12-31 0001421876 ifrs-full:GrossCarryingAmountMember glpg:BrandsLicensesPatentsAndKnowHowMember 2018-01-01 2018-12-31 0001421876 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2018-01-01 2018-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember ifrs-full:ContractAssetsMember 2017-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember 2018-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember glpg:BrandsLicensesPatentsAndKnowHowMember 2017-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember 2018-01-01 2018-12-31 0001421876 glpg:August232019ShareSubscriptionMember glpg:ShareCapitalAndSharePremiumMember glpg:GileadMember 2019-01-01 2019-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember 2017-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember ifrs-full:ComputerSoftwareMember 2017-12-31 0001421876 ifrs-full:GrossCarryingAmountMember ifrs-full:ContractAssetsMember 2017-12-31 0001421876 ifrs-full:GrossCarryingAmountMember glpg:BrandsLicensesPatentsAndKnowHowMember 2017-12-31 0001421876 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2017-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember ifrs-full:ContractAssetsMember 2020-01-01 2020-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember ifrs-full:ContractAssetsMember 2020-12-31 0001421876 ifrs-full:GrossCarryingAmountMember ifrs-full:ContractAssetsMember 2020-12-31 0001421876 ifrs-full:ContractAssetsMember 2020-12-31 0001421876 glpg:BrandsLicensesPatentsAndKnowHowMember 2020-12-31 0001421876 ifrs-full:ComputerSoftwareMember 2020-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember glpg:BrandsLicensesPatentsAndKnowHowMember 2020-01-01 2020-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember glpg:BrandsLicensesPatentsAndKnowHowMember 2020-12-31 0001421876 ifrs-full:GrossCarryingAmountMember glpg:BrandsLicensesPatentsAndKnowHowMember 2020-01-01 2020-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember 2020-01-01 2020-12-31 0001421876 ifrs-full:GrossCarryingAmountMember glpg:BrandsLicensesPatentsAndKnowHowMember 2020-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember ifrs-full:ComputerSoftwareMember 2020-01-01 2020-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember 2020-12-31 0001421876 ifrs-full:AccumulatedImpairmentMember ifrs-full:ComputerSoftwareMember 2020-12-31 0001421876 glpg:August232019ShareSubscriptionMember ifrs-full:SharePremiumMember glpg:GileadMember 2019-01-01 2019-12-31 0001421876 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2020-01-01 2020-12-31 0001421876 glpg:OrdinarySharesNoClassMember glpg:August232019ShareSubscriptionMember glpg:ShareCapitalAndSharePremiumMember glpg:GileadMember 2019-01-01 2019-12-31 0001421876 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2020-12-31 0001421876 glpg:OrdinarySharesNoClassMember glpg:August232019ShareSubscriptionMember ifrs-full:SharePremiumMember glpg:GileadMember 2019-01-01 2019-12-31 0001421876 country:NL 2019-12-31 0001421876 ifrs-full:LandAndBuildingsMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2020-12-31 0001421876 ifrs-full:LandAndBuildingsMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2020-01-01 2020-12-31 0001421876 country:BE 2019-12-31 0001421876 glpg:OrdinarySharesNoClassMember glpg:August232019ShareSubscriptionMember ifrs-full:IssuedCapitalMember glpg:GileadMember 2019-01-01 2019-12-31 0001421876 ifrs-full:LandAndBuildingsMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2019-12-31 0001421876 glpg:August232019ShareSubscriptionMember glpg:AmericanDepositaryReceiptsMember glpg:GileadMember 2019-01-01 2019-12-31 0001421876 ifrs-full:LandAndBuildingsMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2019-01-01 2019-12-31 0001421876 ifrs-full:LandAndBuildingsMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2018-12-31 0001421876 ifrs-full:LandAndBuildingsMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001421876 country:BE 2018-01-01 2018-12-31 0001421876 ifrs-full:LandAndBuildingsMember ifrs-full:GrossCarryingAmountMember 2020-01-01 2020-12-31 0001421876 ifrs-full:LandAndBuildingsMember ifrs-full:GrossCarryingAmountMember 2019-12-31 0001421876 ifrs-full:LandAndBuildingsMember ifrs-full:GrossCarryingAmountMember 2019-01-01 2019-12-31 0001421876 country:BE 2019-01-01 2019-12-31 0001421876 country:BE 2020-01-01 2020-12-31 0001421876 ifrs-full:LandAndBuildingsMember 2020-12-31 0001421876 ifrs-full:LandAndBuildingsMember ifrs-full:GrossCarryingAmountMember 2018-12-31 0001421876 ifrs-full:LandAndBuildingsMember 2019-12-31 0001421876 ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember ifrs-full:GrossCarryingAmountMember 2018-12-31 0001421876 glpg:IncreaseDecreaseDueToApplicationOfIfrs16Member ifrs-full:GrossCarryingAmountMember 2018-12-31 0001421876 glpg:Ifrs16Member ifrs-full:LaterThanFiveYearsMember 2020-12-31 0001421876 glpg:Ifrs16Member ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember 2020-12-31 0001421876 glpg:Ifrs16Member ifrs-full:NotLaterThanOneYearMember 2020-12-31 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2020-12-31 0001421876 2020-01-01 2020-12-31 0001421876 glpg:Ifrs16Member 2018-12-31 0001421876 glpg:Ifrs16Member 2020-12-31 0001421876 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2020-12-31 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2020-01-01 2020-12-31 0001421876 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2020-01-01 2020-12-31 0001421876 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2019-12-31 0001421876 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2019-01-01 2019-12-31 0001421876 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2018-12-31 0001421876 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2018-01-01 2018-12-31 0001421876 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2017-12-31 0001421876 ifrs-full:GrossCarryingAmountMember 2020-12-31 0001421876 ifrs-full:GrossCarryingAmountMember 2020-01-01 2020-12-31 0001421876 ifrs-full:GrossCarryingAmountMember 2019-12-31 0001421876 ifrs-full:GrossCarryingAmountMember 2019-01-01 2019-12-31 0001421876 ifrs-full:GrossCarryingAmountMember 2018-12-31 0001421876 ifrs-full:GrossCarryingAmountMember 2018-01-01 2018-12-31 0001421876 ifrs-full:GrossCarryingAmountMember 2017-12-31 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember 2020-12-31 0001421876 glpg:FairValueReMeasurementOfFinancialInstrumentRelatedToIssuanceOfWarrantMember glpg:GileadSciencesIncMember glpg:WarrantAMember 2019-12-31 0001421876 glpg:FideltaD.o.o.Member glpg:SelvitaSAMember ifrs-full:DisposalGroupsClassifiedAsHeldForSaleMember 2021-01-03 2021-01-04 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2019-12-31 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember 2019-12-31 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2019-01-01 2019-12-31 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2018-12-31 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2018-01-01 2018-12-31 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2017-12-31 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember 2018-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2020-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember 2020-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2020-01-01 2020-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2019-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2019-01-01 2019-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2018-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2018-01-01 2018-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember 2019-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2017-12-31 0001421876 glpg:InstallationAndMachineryMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2020-12-31 0001421876 glpg:InstallationAndMachineryMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2020-01-01 2020-12-31 0001421876 glpg:InstallationAndMachineryMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2019-12-31 0001421876 glpg:InstallationAndMachineryMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2019-01-01 2019-12-31 0001421876 glpg:InstallationAndMachineryMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2018-12-31 0001421876 glpg:InstallationAndMachineryMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2018-01-01 2018-12-31 0001421876 glpg:InstallationAndMachineryMember ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2017-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember 2018-12-31 0001421876 glpg:InstallationAndMachineryMember 2020-12-31 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001421876 glpg:InstallationAndMachineryMember 2019-12-31 0001421876 glpg:InstallationAndMachineryMember 2018-12-31 0001421876 glpg:GileadMember glpg:ReassessmentResponsibilitiesMember glpg:FilgotinibDrugLicenseMember 2020-12-15 2020-12-15 0001421876 glpg:InstallationAndMachineryMember ifrs-full:GrossCarryingAmountMember 2020-12-31 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember ifrs-full:GrossCarryingAmountMember 2020-01-01 2020-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember ifrs-full:GrossCarryingAmountMember 2020-01-01 2020-12-31 0001421876 country:NL 2020-12-31 0001421876 country:BE 2020-12-31 0001421876 glpg:Ifrs16Member 2019-12-31 0001421876 glpg:FairValueReMeasurementOfFinancialInstrumentRelatedToIssuanceOfInitialWarrantBMember 2019-01-01 2019-12-31 0001421876 glpg:InstallationAndMachineryMember ifrs-full:GrossCarryingAmountMember 2020-01-01 2020-12-31 0001421876 glpg:FairValueReMeasurementOfFinancialInstrumentRelatedToIssuanceOfInitialWarrantBMember 2020-01-01 2020-12-31 0001421876 glpg:FairValueReMeasurementOfShareSubscriptionAgreementMember 2019-01-01 2019-12-31 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember ifrs-full:GrossCarryingAmountMember 2019-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember ifrs-full:GrossCarryingAmountMember 2019-12-31 0001421876 glpg:FairValueReMeasurementOfShareSubscriptionAgreementMember 2020-01-01 2020-12-31 0001421876 glpg:InstallationAndMachineryMember ifrs-full:GrossCarryingAmountMember 2019-12-31 0001421876 glpg:WarrantsPlan2018RmvAllocatedOnApril2018Member 2020-01-01 2020-12-31 0001421876 glpg:WarrantsPlan2018AllocatedOnApril2018Member 2020-01-01 2020-12-31 0001421876 glpg:WarrantsPlan2019AllocatedOnApril2019Member 2020-01-01 2020-12-31 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember ifrs-full:GrossCarryingAmountMember 2019-01-01 2019-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember ifrs-full:GrossCarryingAmountMember 2019-01-01 2019-12-31 0001421876 glpg:InstallationAndMachineryMember ifrs-full:GrossCarryingAmountMember 2019-01-01 2019-12-31 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember ifrs-full:GrossCarryingAmountMember 2018-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember ifrs-full:GrossCarryingAmountMember 2018-12-31 0001421876 glpg:FairValueReMeasurementOfFinancialInstrumentRelatedToIssuanceOfInitialWarrantBMember glpg:GileadSciencesIncMember glpg:WarrantBMember 2019-10-22 0001421876 glpg:FairValueReMeasurementOfFinancialInstrumentRelatedToIssuanceOfWarrantMember glpg:GileadSciencesIncMember glpg:WarrantAMember 2019-10-22 0001421876 glpg:GileadMember ifrs-full:TopOfRangeMember srt:EuropeMember glpg:FilgotinibDrugLicenseMember 2020-12-31 0001421876 glpg:GileadMember ifrs-full:BottomOfRangeMember srt:EuropeMember glpg:FilgotinibDrugLicenseMember 2020-12-31 0001421876 glpg:FilgotinibDrugLicenseMember glpg:GileadSciencesIncMember ifrs-full:TopOfRangeMember 2020-01-01 2020-12-31 0001421876 glpg:GileadSciencesIncMember ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember glpg:GileadCollaborationAgreementForZiritaxestatMember 2020-01-01 2020-12-31 0001421876 glpg:NovartisMember ifrs-full:GoodsOrServicesTransferredOverTimeMember ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member glpg:CollaborationAgreementForMor106Member 2019-01-01 2019-12-31 0001421876 glpg:ServierMember ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member glpg:CollaborationAgreementForOsteoarthritisMember 2019-01-01 2019-12-31 0001421876 glpg:NovartisMember ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member glpg:CollaborationAgreementForMor106Member 2019-01-01 2019-12-31 0001421876 glpg:AbbvieMember ifrs-full:GoodsOrServicesTransferredOverTimeMember ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member glpg:CollaborationAgreementForCfMember 2019-01-01 2019-12-31 0001421876 glpg:GileadSciencesIncMember ifrs-full:GoodsOrServicesTransferredOverTimeMember ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member glpg:CollaborationAgreementForFilgotinibMember 2019-01-01 2019-12-31 0001421876 glpg:InstallationAndMachineryMember ifrs-full:GrossCarryingAmountMember 2018-12-31 0001421876 glpg:OtherResearchAndDevelopmentProgramMember 2018-01-01 2018-12-31 0001421876 glpg:OtherResearchAndDevelopmentProgramMember 2019-01-01 2019-12-31 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember ifrs-full:GrossCarryingAmountMember 2018-01-01 2018-12-31 0001421876 glpg:OtherResearchAndDevelopmentProgramMember 2020-01-01 2020-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember ifrs-full:GrossCarryingAmountMember 2018-01-01 2018-12-31 0001421876 glpg:InstallationAndMachineryMember ifrs-full:GrossCarryingAmountMember 2018-01-01 2018-12-31 0001421876 ifrs-full:OtherPropertyPlantAndEquipmentMember ifrs-full:GrossCarryingAmountMember 2017-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember ifrs-full:GrossCarryingAmountMember 2017-12-31 0001421876 glpg:AtdProgramMember 2018-01-01 2018-12-31 0001421876 glpg:AtdProgramMember 2019-01-01 2019-12-31 0001421876 glpg:InstallationAndMachineryMember ifrs-full:GrossCarryingAmountMember 2017-12-31 0001421876 glpg:AtdProgramMember 2020-01-01 2020-12-31 0001421876 glpg:Ifrs16Member ifrs-full:LaterThanFiveYearsMember 2019-12-31 0001421876 glpg:CfProgramMember 2018-01-01 2018-12-31 0001421876 glpg:CfProgramMember 2019-01-01 2019-12-31 0001421876 glpg:Ifrs16Member ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember 2019-12-31 0001421876 glpg:CfProgramMember 2020-01-01 2020-12-31 0001421876 glpg:Ifrs16Member ifrs-full:NotLaterThanOneYearMember 2019-12-31 0001421876 glpg:ToledoProgramMember 2018-01-01 2018-12-31 0001421876 glpg:ToledoProgramMember 2019-01-01 2019-12-31 0001421876 ifrs-full:AssociatesMember ifrs-full:TopOfRangeMember 2019-10-22 2019-10-22 0001421876 glpg:ToledoProgramMember 2020-01-01 2020-12-31 0001421876 glpg:OaProgramMember 2018-01-01 2018-12-31 0001421876 glpg:OaProgramMember 2019-01-01 2019-12-31 0001421876 glpg:OaProgramMember 2020-01-01 2020-12-31 0001421876 glpg:FilgotinibProgramMember 2018-01-01 2018-12-31 0001421876 glpg:FilgotinibProgramMember 2019-01-01 2019-12-31 0001421876 glpg:FilgotinibProgramMember 2020-01-01 2020-12-31 0001421876 glpg:GileadSciencesIncMember 2020-01-01 2020-12-31 0001421876 glpg:OtherDeferredIncomeMember 2020-12-31 0001421876 glpg:OtherDeferredIncomeMember 2019-12-31 0001421876 glpg:OtherDeferredIncomeMember 2019-01-01 2019-12-31 0001421876 glpg:OtherDeferredIncomeMember 2018-12-31 0001421876 glpg:OtherDeferredIncomeMember 2018-01-01 2018-12-31 0001421876 glpg:OtherDeferredIncomeMember 2017-12-31 0001421876 glpg:FeeForServicesSegmentMember 2020-01-01 2020-12-31 0001421876 glpg:FeeForServicesSegmentMember 2019-12-31 0001421876 glpg:FeeForServicesSegmentMember 2019-01-01 2019-12-31 0001421876 glpg:FeeForServicesSegmentMember 2018-12-31 0001421876 glpg:FeeForServicesSegmentMember 2018-01-01 2018-12-31 0001421876 glpg:FeeForServicesSegmentMember 2017-12-31 0001421876 glpg:GileadSciencesIncMember ifrs-full:DerivativesMember 2020-01-01 2020-12-31 0001421876 glpg:CollaborationAgreementForOsteoarthritisMember glpg:ServierMember 2017-12-31 0001421876 glpg:CollaborationAgreementForCFMember glpg:AbbvieMember 2019-01-01 2019-12-31 0001421876 glpg:CollaborationAgreementForCFMember glpg:AbbvieMember 2018-12-31 0001421876 glpg:CollaborationAgreementForCFMember glpg:AbbvieMember 2018-01-01 2018-12-31 0001421876 glpg:GileadCollaborationAgreementForDrugDiscoveryPlatformMember glpg:GileadSciencesIncMember 2020-12-31 0001421876 glpg:GileadCollaborationAgreementForDrugDiscoveryPlatformMember glpg:GileadSciencesIncMember 2019-12-31 0001421876 glpg:GileadCollaborationAgreementForDrugDiscoveryPlatformMember glpg:GileadSciencesIncMember 2019-01-01 2019-12-31 0001421876 glpg:CollaborationAgreementForFilgotinibMember glpg:GileadSciencesIncMember 2020-01-01 2020-12-31 0001421876 glpg:CollaborationAgreementForFilgotinibMember glpg:GileadSciencesIncMember 2019-01-01 2019-12-31 0001421876 glpg:CollaborationAgreementForFilgotinibMember glpg:GileadSciencesIncMember 2018-01-01 2018-12-31 0001421876 glpg:CollaborationAgreementForFilgotinibMember glpg:GileadSciencesIncMember 2017-12-31 0001421876 glpg:CollaborationAgreementForFilgotinibMember glpg:GileadSciencesIncMember 2020-12-31 0001421876 glpg:CollaborationAgreementForFilgotinibMember glpg:GileadSciencesIncMember 2018-12-31 0001421876 glpg:CollaborationAgreementForFilgotinibMember glpg:GileadSciencesIncMember 2019-12-31 0001421876 glpg:FilgotinibDrugLicenseMember ifrs-full:AssociatesMember 2020-01-01 2020-12-31 0001421876 glpg:FilgotinibDrugLicenseMember ifrs-full:AssociatesMember 2019-01-01 2019-12-31 0001421876 ifrs-full:AssociatesMember glpg:Glpg1690LicenseMember 2020-01-01 2020-12-31 0001421876 ifrs-full:AssociatesMember glpg:Glpg1690LicenseMember 2019-01-01 2019-12-31 0001421876 glpg:XenometrixInc.Member country:US 2018-01-01 2018-12-31 0001421876 glpg:FideltaD.o.o.Member country:HR 2018-01-01 2018-12-31 0001421876 glpg:GalapagosSasuMember country:FR 2018-01-01 2018-12-31 0001421876 glpg:GalapagosRealEstateTwoBvMember country:BE 2018-01-01 2018-12-31 0001421876 glpg:GalapagosRealEstateOneBvMember country:BE 2018-01-01 2018-12-31 0001421876 glpg:GalapagosInc.Member country:US 2018-01-01 2018-12-31 0001421876 glpg:GalapagosGmbhMember country:CH 2018-01-01 2018-12-31 0001421876 glpg:GalapagosBiotechLtd.Member country:GB 2018-01-01 2018-12-31 0001421876 glpg:GalapagosB.vMember country:NL 2018-01-01 2018-12-31 0001421876 country:CH glpg:BiofocusDpiAgMember 2018-01-01 2018-12-31 0001421876 glpg:XenometrixInc.Member country:US 2019-01-01 2019-12-31 0001421876 glpg:FideltaD.o.o.Member country:HR 2019-01-01 2019-12-31 0001421876 glpg:GalapagosSasuMember country:FR 2019-01-01 2019-12-31 0001421876 glpg:GalapagosRealEstateB.v.Member country:NL 2019-01-01 2019-12-31 0001421876 glpg:GalapagosRealEstateTwoBvMember country:BE 2019-01-01 2019-12-31 0001421876 glpg:GalapagosRealEstateOneBvMember country:BE 2019-01-01 2019-12-31 0001421876 glpg:GalapagosInc.Member country:US 2019-01-01 2019-12-31 0001421876 glpg:GalapagosGmbhMember country:CH 2019-01-01 2019-12-31 0001421876 ifrs-full:LaterThanFiveYearsMember 2018-12-31 0001421876 ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember 2018-12-31 0001421876 ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember 2018-12-31 0001421876 ifrs-full:NotLaterThanOneYearMember 2018-12-31 0001421876 glpg:GalapagosBiotechLtd.Member country:GB 2019-01-01 2019-12-31 0001421876 glpg:GalapagosB.vMember country:NL 2019-01-01 2019-12-31 0001421876 glpg:GalapagosBiopharmaGmbhMember country:DE 2019-01-01 2019-12-31 0001421876 ifrs-full:LaterThanFiveYearsMember 2019-12-31 0001421876 ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember 2020-12-31 0001421876 ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember 2020-12-31 0001421876 glpg:GalapagosBiopharmaS.r.lMember country:IT 2019-01-01 2019-12-31 0001421876 glpg:GalapagosBiopharmaS.l.uMember country:ES 2019-01-01 2019-12-31 0001421876 ifrs-full:NotLaterThanOneYearMember 2020-12-31 0001421876 country:NL glpg:GalapagosBiopharmaB.v.Member 2020-01-01 2020-12-31 0001421876 ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember 2019-12-31 0001421876 ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember 2019-12-31 0001421876 ifrs-full:NotLaterThanOneYearMember 2019-12-31 0001421876 2019-07-14 0001421876 glpg:OtherMember 2018-12-31 0001421876 glpg:OtherMember 2019-12-31 0001421876 country:BE glpg:GalapagosBiopharmaB.v.Member 2020-01-01 2020-12-31 0001421876 country:CH glpg:BiofocusDpiAgMember 2020-01-01 2020-12-31 0001421876 glpg:XenometrixInc.Member country:US 2020-01-01 2020-12-31 0001421876 glpg:FideltaD.o.o.Member country:HR 2020-01-01 2020-12-31 0001421876 glpg:OtherMember 2020-12-31 0001421876 glpg:ExecutiveTeamMember 2018-12-31 0001421876 glpg:ExecutiveTeamMember 2019-12-31 0001421876 glpg:ExecutiveTeamMember 2020-12-31 0001421876 glpg:NonExecutiveDirectorsMember 2018-12-31 0001421876 glpg:NonExecutiveDirectorsMember 2019-12-31 0001421876 glpg:NonExecutiveDirectorsMember 2020-12-31 0001421876 glpg:GalapagosSasuMember country:FR 2020-01-01 2020-12-31 0001421876 glpg:GalapagosRealEstateB.v.Member country:NL 2020-01-01 2020-12-31 0001421876 glpg:GalapagosRealEstateTwoBvMember country:BE 2020-01-01 2020-12-31 0001421876 glpg:GalapagosRealEstateOneBvMember country:BE 2020-01-01 2020-12-31 0001421876 glpg:GalapagosInc.Member country:US 2020-01-01 2020-12-31 0001421876 glpg:GalapagosGmbhMember country:CH 2020-01-01 2020-12-31 0001421876 glpg:GalapagosBiotechLtd.Member country:GB 2020-01-01 2020-12-31 0001421876 glpg:GalapagosB.vMember country:NL 2020-01-01 2020-12-31 0001421876 glpg:WarrantsPlan2019RmvAllocatedOnApril2019Member 2020-01-01 2020-12-31 0001421876 glpg:GalapagosBiopharmaGmbhMember country:DE 2020-01-01 2020-12-31 0001421876 glpg:GalapagosBiopharmaS.r.lMember country:IT 2020-01-01 2020-12-31 0001421876 glpg:GalapagosBiopharmaS.l.uMember country:ES 2020-01-01 2020-12-31 0001421876 country:NL glpg:GalapagosBiopharmaB.v.Member 2019-01-01 2019-12-31 0001421876 country:BE glpg:GalapagosBiopharmaB.v.Member 2019-01-01 2019-12-31 0001421876 glpg:IfrsRestrictedStockUnitsRsusMember 2020-01-01 2020-12-31 0001421876 glpg:WarrantsMember 2020-01-01 2020-12-31 0001421876 country:CH glpg:BiofocusDpiAgMember 2019-01-01 2019-12-31 0001421876 ifrs-full:CurrencyRiskMember glpg:UsdGbpExchangeRateValueMember 2020-01-01 2020-12-31 0001421876 ifrs-full:CurrencyRiskMember glpg:EuroHrKunasExchangeRateValueMember 2020-01-01 2020-12-31 0001421876 ifrs-full:CurrencyRiskMember glpg:EuroChFrancsExchangeRateValueMember 2020-01-01 2020-12-31 0001421876 glpg:IfrsRestrictedStockUnitsRsusMember 2019-01-01 2019-12-31 0001421876 glpg:WarrantsMember 2018-01-01 2018-12-31 0001421876 glpg:WarrantsMember 2019-01-01 2019-12-31 0001421876 glpg:MaryKerrMember 2018-01-01 2018-12-31 0001421876 glpg:ChristineMummeryMember 2018-01-01 2018-12-31 0001421876 glpg:KatrineBosleyMember 2018-01-01 2018-12-31 0001421876 glpg:WernerCautreelsMember 2018-01-01 2018-12-31 0001421876 glpg:HowardRoweMember 2018-01-01 2018-12-31 0001421876 glpg:HarroldVanBarlingenMember 2018-01-01 2018-12-31 0001421876 glpg:RajParekhMember 2018-01-01 2018-12-31 0001421876 glpg:PeterGuenterMember 2019-01-01 2019-12-31 0001421876 glpg:ChristineMummeryMember 2019-01-01 2019-12-31 0001421876 glpg:MaryKerrMember 2019-01-01 2019-12-31 0001421876 glpg:KatrineBosleyMember 2019-01-01 2019-12-31 0001421876 glpg:WernerCautreelsMember 2019-01-01 2019-12-31 0001421876 glpg:HowardRoweMember 2019-01-01 2019-12-31 0001421876 glpg:RajParekhMember 2019-01-01 2019-12-31 0001421876 glpg:ExecutiveCommitteeMembersAsGroupMember 2018-01-01 2018-12-31 0001421876 glpg:ExecutiveCommitteeMembersAsGroupMember 2019-01-01 2019-12-31 0001421876 ifrs-full:AssociatesMember 2020-12-31 0001421876 glpg:GileadCollaborationAgreementForDrugDiscoveryPlatformMember 2019-12-31 0001421876 ifrs-full:AssociatesMember 2020-01-01 2020-12-31 0001421876 glpg:GileadCollaborationAgreementForDrugDiscoveryPlatformMember 2020-01-01 2020-12-31 0001421876 glpg:GileadCollaborationAgreementForDrugDiscoveryPlatformMember 2019-01-01 2019-12-31 0001421876 ifrs-full:AssociatesMember 2019-11-06 2019-11-06 0001421876 ifrs-full:AssociatesMember 2019-12-31 0001421876 ifrs-full:InterestRateRiskMember 2020-01-01 2020-12-31 0001421876 ifrs-full:InterestRateRiskMember 2018-01-01 2018-12-31 0001421876 ifrs-full:InterestRateRiskMember 2019-01-01 2019-12-31 0001421876 ifrs-full:InterestRateRiskMember 2018-12-31 0001421876 ifrs-full:InterestRateRiskMember 2020-12-31 0001421876 ifrs-full:InterestRateRiskMember 2019-12-31 0001421876 ifrs-full:LeaseLiabilitiesMember 2020-12-31 0001421876 glpg:CurrentFinancialInstrumentsLiabilitiesMember 2020-12-31 0001421876 glpg:TradeAndOtherReceivablesMember 2020-12-31 0001421876 glpg:RestrictedCashMember 2020-12-31 0001421876 glpg:CashAndCashEquivalentMember 2020-12-31 0001421876 glpg:CurrentFinancialInvestmentsMember 2020-12-31 0001421876 ifrs-full:LeaseLiabilitiesMember 2019-12-31 0001421876 glpg:IncreaseDecreaseDueToApplicationOfIfrs16Member 2019-01-01 0001421876 glpg:IncreaseDecreaseDueToApplicationOfIfrs16Member 2018-12-31 0001421876 glpg:CurrentFinancialInstrumentsLiabilitiesMember 2019-12-31 0001421876 ifrs-full:CurrencyRiskMember glpg:EuroGbpExchangeRateValueMember 2020-01-01 2020-12-31 0001421876 ifrs-full:CurrencyRiskMember glpg:EuroUsdExchangeRateValueMember 2020-01-01 2020-12-31 0001421876 glpg:Ifrs16Member 2020-01-01 2020-12-31 0001421876 ifrs-full:CurrencyRiskMember glpg:UsdGbpExchangeRateValueMember 2018-01-01 2018-12-31 0001421876 ifrs-full:CurrencyRiskMember glpg:EuroHrKunasExchangeRateValueMember 2018-01-01 2018-12-31 0001421876 ifrs-full:CurrencyRiskMember glpg:EuroUsdExchangeRateValueMember 2018-01-01 2018-12-31 0001421876 ifrs-full:CurrencyRiskMember glpg:EuroGbpExchangeRateValueMember 2018-01-01 2018-12-31 0001421876 ifrs-full:CurrencyRiskMember glpg:EuroChFrancsExchangeRateValueMember 2018-01-01 2018-12-31 0001421876 ifrs-full:CurrencyRiskMember glpg:UsdGbpExchangeRateValueMember 2019-01-01 2019-12-31 0001421876 ifrs-full:CurrencyRiskMember glpg:EuroUsdExchangeRateValueMember 2019-01-01 2019-12-31 0001421876 ifrs-full:CurrencyRiskMember glpg:EuroHrKunasExchangeRateValueMember 2019-01-01 2019-12-31 0001421876 ifrs-full:CurrencyRiskMember glpg:EuroGbpExchangeRateValueMember 2019-01-01 2019-12-31 0001421876 ifrs-full:CurrencyRiskMember glpg:EuroChFrancsExchangeRateValueMember 2019-01-01 2019-12-31 0001421876 ifrs-full:TradeReceivablesMember ifrs-full:LaterThanFourMonthsMember ifrs-full:CreditRiskMember 2018-12-31 0001421876 ifrs-full:TradeReceivablesMember ifrs-full:LaterThanFourMonthsMember ifrs-full:CreditRiskMember 2019-12-31 0001421876 glpg:CurrentFinancialInvestmentsMember 2019-12-31 0001421876 glpg:TradeAndOtherReceivablesMember 2018-12-31 0001421876 glpg:TradeAndOtherReceivablesMember 2019-12-31 0001421876 glpg:RestrictedCashMember 2018-12-31 0001421876 glpg:RestrictedCashMember 2019-12-31 0001421876 glpg:CashAndCashEquivalentMember 2018-12-31 0001421876 glpg:CashAndCashEquivalentMember 2019-12-31 0001421876 ifrs-full:CurrencyRiskMember 2020-01-01 2020-12-31 0001421876 glpg:GileadMember 2019-11-06 2019-11-06 0001421876 glpg:GileadMember 2019-10-22 2019-10-22 0001421876 glpg:WarrantBMember 2019-10-22 2019-10-22 0001421876 ifrs-full:TradeReceivablesMember ifrs-full:LaterThanThreeMonthsAndNotLaterThanFourMonthsMember ifrs-full:CreditRiskMember 2020-12-31 0001421876 glpg:GileadMember 2019-07-14 2019-07-14 0001421876 ifrs-full:TradeReceivablesMember ifrs-full:LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember ifrs-full:CreditRiskMember 2020-12-31 0001421876 ifrs-full:TradeReceivablesMember ifrs-full:LaterThanThreeMonthsAndNotLaterThanFourMonthsMember ifrs-full:CreditRiskMember 2018-12-31 0001421876 ifrs-full:TradeReceivablesMember ifrs-full:LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember ifrs-full:CreditRiskMember 2018-12-31 0001421876 glpg:FilgotinibDrugLicenseMember 2019-07-14 2019-07-14 0001421876 ifrs-full:TradeReceivablesMember ifrs-full:LaterThanTwoMonthsAndNotLaterThanThreeMonthsMember ifrs-full:CreditRiskMember 2019-12-31 0001421876 glpg:Glpg1972LicenseMember 2019-07-14 2019-07-14 0001421876 glpg:BrandsLicensesPatentsAndKnowHowMember ifrs-full:TopOfRangeMember 2020-01-01 2020-12-31 0001421876 glpg:Glpg1690LicenseMember 2019-07-14 2019-07-14 0001421876 glpg:BrandsLicensesPatentsAndKnowHowMember ifrs-full:BottomOfRangeMember 2020-01-01 2020-12-31 0001421876 ifrs-full:ComputerSoftwareMember ifrs-full:TopOfRangeMember 2020-01-01 2020-12-31 0001421876 glpg:GileadCollaborationAgreementForDrugDiscoveryPlatformMember glpg:GileadSciencesIncMember ifrs-full:GoodsOrServicesTransferredOverTimeMember 2018-01-01 2018-12-31 0001421876 glpg:GileadCollaborationAgreementForZiritaxestatMember glpg:GileadSciencesIncMember ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2018-01-01 2018-12-31 0001421876 ifrs-full:ComputerSoftwareMember ifrs-full:BottomOfRangeMember 2020-01-01 2020-12-31 0001421876 glpg:GileadSciencesIncMember ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember glpg:GileadCollaborationAgreementForZiritaxestatMember 2019-01-01 2019-12-31 0001421876 glpg:CollaborationAgreementForMor106Member glpg:NovartisMember ifrs-full:GoodsOrServicesTransferredOverTimeMember 2018-01-01 2018-12-31 0001421876 ifrs-full:SharePremiumMember 2020-01-01 2020-12-31 0001421876 ifrs-full:IssuedCapitalMember 2020-01-01 2020-12-31 0001421876 ifrs-full:OtherReservesMember 2020-01-01 2020-12-31 0001421876 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-01-01 2020-12-31 0001421876 ifrs-full:RetainedEarningsMember 2020-01-01 2020-12-31 0001421876 ifrs-full:RetainedEarningsMember 2020-12-31 0001421876 glpg:FairValueReMeasurementOfFinancialInstrumentRelatedToIssuanceOfInitialWarrantBMember glpg:GileadSciencesIncMember glpg:WarrantBMember 2020-01-01 2020-12-31 0001421876 glpg:FairValueReMeasurementOfFinancialInstrumentRelatedToIssuanceOfInitialWarrantBMember glpg:GileadSciencesIncMember glpg:WarrantBMember 2020-12-31 0001421876 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-12-31 0001421876 ifrs-full:SharePremiumMember 2020-12-31 0001421876 ifrs-full:IssuedCapitalMember 2020-12-31 0001421876 ifrs-full:OtherReservesMember 2020-12-31 0001421876 glpg:CurrentlyReportedMember 2018-12-31 0001421876 glpg:CurrentlyReportedMember 2017-12-31 0001421876 ifrs-full:InAccordanceWithIFRS9Member 2018-12-31 0001421876 ifrs-full:RetainedEarningsMember 2018-12-31 0001421876 ifrs-full:OtherReservesMember 2018-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember ifrs-full:TopOfRangeMember 2020-01-01 2020-12-31 0001421876 glpg:FurnitureFixturesAndVehiclesMember ifrs-full:BottomOfRangeMember 2020-01-01 2020-12-31 0001421876 glpg:InstallationAndMachineryMember ifrs-full:TopOfRangeMember 2020-01-01 2020-12-31 0001421876 glpg:InstallationAndMachineryMember ifrs-full:BottomOfRangeMember 2020-01-01 2020-12-31 0001421876 glpg:WarrantAMember glpg:GileadMember 2019-11-06 2019-11-06 0001421876 glpg:GileadMember ifrs-full:TopOfRangeMember 2019-10-22 2019-10-22 0001421876 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2018-12-31 0001421876 ifrs-full:SharePremiumMember 2018-12-31 0001421876 ifrs-full:IssuedCapitalMember 2018-12-31 0001421876 ifrs-full:SharePremiumMember 2018-01-01 2018-12-31 0001421876 ifrs-full:IssuedCapitalMember 2018-01-01 2018-12-31 0001421876 ifrs-full:OtherReservesMember 2018-01-01 2018-12-31 0001421876 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2018-01-01 2018-12-31 0001421876 ifrs-full:RetainedEarningsMember 2018-01-01 2018-12-31 0001421876 ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member 2017-12-31 0001421876 ifrs-full:RetainedEarningsMember 2017-12-31 0001421876 ifrs-full:TopOfRangeMember ifrs-full:ForeignCountriesMember 2019-07-14 2019-07-14 0001421876 ifrs-full:OtherReservesMember 2017-12-31 0001421876 ifrs-full:BottomOfRangeMember ifrs-full:ForeignCountriesMember 2019-07-14 2019-07-14 0001421876 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2017-12-31 0001421876 ifrs-full:SharePremiumMember 2017-12-31 0001421876 ifrs-full:IssuedCapitalMember 2017-12-31 0001421876 glpg:Glpg1972LicenseMember country:US 2019-07-14 2019-07-14 0001421876 glpg:WarrantAMember glpg:GileadSciencesIncMember 2018-01-01 2018-12-31 0001421876 glpg:WarrantAMember glpg:GileadSciencesIncMember 2020-01-01 2020-12-31 0001421876 ifrs-full:RetainedEarningsMember glpg:CurrentlyReportedMember 2018-12-31 0001421876 ifrs-full:RetainedEarningsMember 2019-01-01 2019-12-31 0001421876 ifrs-full:RetainedEarningsMember 2019-12-31 0001421876 ifrs-full:OtherReservesMember 2019-01-01 2019-12-31 0001421876 ifrs-full:OtherReservesMember 2019-12-31 0001421876 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2019-01-01 2019-12-31 0001421876 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2019-12-31 0001421876 ifrs-full:OtherReservesMember glpg:CurrentlyReportedMember 2018-12-31 0001421876 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember glpg:CurrentlyReportedMember 2018-12-31 0001421876 ifrs-full:SharePremiumMember glpg:CurrentlyReportedMember 2018-12-31 0001421876 ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember ifrs-full:LandAndBuildingsMember ifrs-full:GrossCarryingAmountMember 2018-12-31 0001421876 ifrs-full:SharePremiumMember 2019-01-01 2019-12-31 0001421876 glpg:IncreaseDecreaseDueToApplicationOfIfrs16Member ifrs-full:LandAndBuildingsMember ifrs-full:GrossCarryingAmountMember 2018-12-31 0001421876 ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember glpg:InstallationAndMachineryMember ifrs-full:GrossCarryingAmountMember 2018-12-31 0001421876 glpg:IncreaseDecreaseDueToApplicationOfIfrs16Member glpg:InstallationAndMachineryMember ifrs-full:GrossCarryingAmountMember 2018-12-31 0001421876 ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember glpg:FurnitureFixturesAndVehiclesMember ifrs-full:GrossCarryingAmountMember 2018-12-31 0001421876 glpg:IncreaseDecreaseDueToApplicationOfIfrs16Member glpg:FurnitureFixturesAndVehiclesMember ifrs-full:GrossCarryingAmountMember 2018-12-31 0001421876 ifrs-full:IssuedCapitalMember glpg:CurrentlyReportedMember 2018-12-31 0001421876 glpg:FairValueReMeasurementOfFinancialInstrumentRelatedToIssuanceOfInitialWarrantBMember glpg:GileadSciencesIncMember glpg:WarrantBMember 2019-12-31 0001421876 glpg:FairValueReMeasurementOfFinancialInstrumentRelatedToIssuanceOfWarrantMember glpg:GileadSciencesIncMember glpg:WarrantAMember 2019-11-06 2019-11-06 0001421876 ifrs-full:RetainedEarningsMember glpg:CurrentlyReportedMember 2017-12-31 0001421876 ifrs-full:OtherReservesMember glpg:CurrentlyReportedMember 2017-12-31 0001421876 ifrs-full:DerivativesMember glpg:GileadSciencesIncMember ifrs-full:Level3OfFairValueHierarchyMember 2019-12-31 0001421876 ifrs-full:DerivativesMember glpg:GileadSciencesIncMember ifrs-full:Level3OfFairValueHierarchyMember 2019-08-23 2019-08-23 0001421876 ifrs-full:DerivativesMember glpg:GileadSciencesIncMember ifrs-full:Level3OfFairValueHierarchyMember 2019-08-23 0001421876 ifrs-full:DerivativesMember glpg:GileadSciencesIncMember ifrs-full:Level3OfFairValueHierarchyMember 2019-07-14 0001421876 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember glpg:CurrentlyReportedMember 2017-12-31 0001421876 glpg:CollaborationAgreementForOsteoarthritisMember glpg:ServierMember ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member 2017-12-31 0001421876 glpg:CollaborationAgreementForCFMember glpg:AbbvieMember ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member 2017-12-31 0001421876 glpg:CollaborationAgreementForFilgotinibMember glpg:GileadSciencesIncMember ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member 2017-12-31 0001421876 ifrs-full:LaterThanFourMonthsMember ifrs-full:TradeReceivablesMember ifrs-full:CreditRiskMember 2020-12-31 0001421876 ifrs-full:SharePremiumMember glpg:CurrentlyReportedMember 2017-12-31 0001421876 ifrs-full:SharePremiumMember 2019-12-31 0001421876 ifrs-full:IssuedCapitalMember 2019-01-01 2019-12-31 0001421876 ifrs-full:IssuedCapitalMember glpg:CurrentlyReportedMember 2017-12-31 0001421876 ifrs-full:RetainedEarningsMember ifrs-full:InAccordanceWithIFRS9Member 2018-12-31 0001421876 ifrs-full:RetainedEarningsMember ifrs-full:InAccordanceWithIFRS9Member 2017-12-31 0001421876 ifrs-full:OtherReservesMember ifrs-full:InAccordanceWithIFRS9Member 2017-12-31 0001421876 ifrs-full:RetainedEarningsMember ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member 2017-12-31 0001421876 ifrs-full:SharePremiumMember glpg:WarrantAMember glpg:GileadSciencesIncMember 2019-01-01 2019-12-31 0001421876 glpg:WarrantAMember glpg:GileadSciencesIncMember 2019-01-01 2019-12-31 0001421876 ifrs-full:IssuedCapitalMember glpg:WarrantAMember glpg:GileadSciencesIncMember 2019-01-01 2019-12-31 0001421876 ifrs-full:IssuedCapitalMember 2019-12-31 0001421876 glpg:FairValueReMeasurementOfFinancialInstrumentRelatedToIssuanceOfWarrantMember glpg:GileadSciencesIncMember glpg:WarrantAMember 2019-10-23 2019-11-06 0001421876 glpg:FairValueReMeasurementOfFinancialInstrumentRelatedToIssuanceOfInitialWarrantBMember glpg:GileadSciencesIncMember glpg:WarrantBMember 2019-10-23 2019-12-31 0001421876 ifrs-full:BottomOfRangeMember ifrs-full:ForeignCountriesMember glpg:GileadCollaborationAgreementForZiritaxestatMember 2019-07-14 2019-07-14 0001421876 ifrs-full:TopOfRangeMember ifrs-full:ForeignCountriesMember glpg:GileadCollaborationAgreementForZiritaxestatMember 2019-07-14 2019-07-14 0001421876 glpg:FilgotinibDrugLicenseMember ifrs-full:BottomOfRangeMember ifrs-full:ForeignCountriesMember 2020-01-01 2020-12-31 0001421876 glpg:FilgotinibDrugLicenseMember ifrs-full:TopOfRangeMember ifrs-full:ForeignCountriesMember 2020-01-01 2020-12-31 0001421876 glpg:GileadCollaborationAgreementForZiritaxestatMember glpg:GileadSciencesIncMember 2019-12-31 0001421876 glpg:GileadCollaborationAgreementForZiritaxestatMember glpg:GileadSciencesIncMember 2020-12-31 0001421876 glpg:GileadSciencesIncMember ifrs-full:DerivativesMember 2019-07-14 0001421876 glpg:FilgotinibAgreement2015Member glpg:FilgotinibPerformanceObligationMember 2019-12-31 0001421876 glpg:MilestonesAchievedDuring2015To2019Member glpg:FilgotinibPerformanceObligationMember 2019-12-31 0001421876 glpg:OptionLicenseAndCollaborationAgreementJuly142019Member glpg:FilgotinibPerformanceObligationMember 2019-07-14 0001421876 glpg:GileadSciencesIncMember glpg:CollaborationAgreementForFilgotinibMember glpg:FilgotinibPerformanceObligationMember 2019-12-31 0001421876 glpg:OtherMovementsIn2020Member glpg:FilgotinibPerformanceObligationMember 2020-12-31 0001421876 glpg:FilgotinibAmendmentDecember152020Member glpg:FilgotinibPerformanceObligationMember 2020-12-15 0001421876 glpg:GileadSciencesIncMember glpg:CollaborationAgreementForFilgotinibMember glpg:FilgotinibPerformanceObligationMember 2020-12-31 0001421876 glpg:GileadSciencesIncMember glpg:FilgotinibPerformanceObligationMember 2019-12-31 0001421876 glpg:GileadSciencesIncMember glpg:FilgotinibPerformanceObligationMember 2020-12-31 0001421876 glpg:FilgotinibDrugLicenseMember glpg:GroupBActivitiesMember glpg:GileadSciencesIncMember 2020-12-31 0001421876 srt:EuropeMember glpg:FilgotinibDrugLicenseMember ifrs-full:BottomOfRangeMember glpg:GileadSciencesIncMember 2020-12-31 0001421876 srt:EuropeMember glpg:FilgotinibDrugLicenseMember ifrs-full:TopOfRangeMember glpg:GileadSciencesIncMember 2020-12-31 0001421876 glpg:FilgotinibDrugLicenseMember glpg:GileadSciencesIncMember 2020-12-31 0001421876 glpg:FilgotinibDrugLicenseMember glpg:ReassessmentResponsibilitiesMember glpg:GileadSciencesIncMember 2020-12-15 2020-12-15 0001421876 glpg:FilgotinibDrugLicenseMember glpg:GileadSciencesIncMember 2020-12-31 0001421876 ifrs-full:DerivativesMember glpg:GileadSciencesIncMember ifrs-full:Level3OfFairValueHierarchyMember 2019-07-15 2019-08-23 0001421876 glpg:SecondCollaborationAgreementForFilgotinibMember 2020-01-01 2020-12-31 0001421876 glpg:GileadSciencesIncMember glpg:SecondCollaborationAgreementForFilgotinibMember 2020-01-01 2020-12-31 0001421876 glpg:GileadMember glpg:ReassessmentResponsibilitiesMember glpg:FilgotinibDrugLicenseMember 2020-12-31 0001421876 ifrs-full:AnnouncementOfPlanToDiscontinueOperationMember 2021-04-01 2021-04-01 0001421876 ifrs-full:ParentMember glpg:InvestmentDeductionCarriedForwardToBeOffsetAgainstFutureIncomeMember 2020-12-31 0001421876 ifrs-full:ParentMember glpg:DividendReceivedDeductionCarriedForwardToBeOffsetAgainstFutureIncomeMember 2020-12-31 0001421876 ifrs-full:ParentMember glpg:InvestmentDeductionCarriedForwardToBeOffsetAgainstFutureIncomeMember 2019-12-31 0001421876 ifrs-full:ParentMember glpg:InvestmentDeductionCarriedForwardToBeOffsetAgainstFutureIncomeMember 2018-12-31 0001421876 ifrs-full:ParentMember glpg:DueToInnovationIncomeDeductionMember 2020-01-01 2020-12-31 0001421876 ifrs-full:ParentMember glpg:DueToInnovationIncomeDeductionMember 2019-01-01 2019-12-31 0001421876 ifrs-full:ParentMember glpg:DueToInnovationIncomeDeductionMember 2018-01-01 2018-12-31 0001421876 glpg:LaterThanOneYearAndNotLaterThanFifteenYearsMember 2020-01-01 2020-12-31 0001421876 ifrs-full:CountryOfDomicileMember ifrs-full:ParentMember 2020-01-01 2020-12-31 xbrli:shares xbrli:pure iso4217:EUR utr:D utr:Y iso4217:USD iso4217:EUR xbrli:shares glpg:subsidiary glpg:EquityInstruments glpg:item glpg:Milestone glpg:lease glpg:employee glpg:segment

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 20-F

 

(Mark One)

         REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

         ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2020

OR

         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

For the transition period from __________ to __________

OR

         SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report __________

Commission file number 001-37384

 

 

GALAPAGOS NV

(Exact name of Registrant as specified in its charter and translation of Registrant’s name into English)

 

 

Belgium

(Jurisdiction of incorporation or organization)

Generaal De Wittelaan L11 A3

2800 Mechelen, Belgium

(Address of principal executive offices)

Onno van de Stolpe

Chief Executive Officer

Galapagos NV

Generaal De Wittelaan L11 A3

2800 Mechelen, Belgium

Tel: +32 15 342 900 Fax: +32 15 342 901

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act.

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

American Depositary Shares, each representing one

GLPG

The Nasdaq Stock Market LLC

ordinary share, no par value per share

 

 

Ordinary shares, no par value per share*

 

The Nasdaq Stock Market LLC*

 

* Not for trading, but only in connection with the registration of the American Depositary Shares.

 

Securities registered or to be registered pursuant to Section 12(g) of the Act. None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. None

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

Ordinary shares, no par value per share: 65,411,767 as of December 31, 2020

 

 


Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.              Yes  ☐ No

 

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days Yes No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

Large accelerated filer   Accelerated filer  Non-accelerated filer   Emerging growth company  


  

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.


 

The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

 

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing: 

 

U.S. GAAP

International Financial Reporting Standards as issued

Other  


 

by the International Accounting Standards Board

 

 

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.     Item 17     Item 18



If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  No

 

 






TABLE OF CONTENTS



Page
INTRODUCTION 1
PART I 5
Item 1       Identity of Directors, Senior Management and Advisers 5
Item 2       Offer Statistics and Expected Timetable 5
Item 3       Key Information 6
A. Selected Financial Data 6
B. Capitalization and Indebtedness 7
C. Reasons for the Offer and Use of Proceeds 7
D. Risk Factors 8
Item 4      Information on the Company 49
A. History and Development of the Company 49
B. Business Overview 49
C. Organizational Structure. 113
D. Property, Plants and Equipment. 113
Item 4A    Unresolved Staff Comments 114
Item 5       Operating and Financial Review and Prospects 114
A. Operating Results 123
B. Liquidity and Capital Resources 142
C. Research and Development, Patents and Licenses, etc 147
D. Trend Information 147
E. Off-Balance Sheet Arrangements 147
F. Tabular Disclosure of Contractual Obligations 147
G. Safe Harbor 148
Item 6  Directors, Senior Management and Employees 148
A. Directors and Senior Management 148
B. Compensation 153
C. Board Practices 168
D. Employees 171
E. Share Ownership 171
Item 7     Major Shareholders and Related Party Transactions 172
A. Major Shareholders 172
B. Related Party Transactions 175
C. Interests of Experts and Counsel 181
Item 8     Financial Information 181
A. Consolidated Statements and Other Financial Information 181
B. Significant Changes 182
Item 9      The Offer and Listing 182
A. Offer and Listing Details 182
B. Plan of Distribution 182
C. Markets 182
D. Selling Shareholders 182
E. Dilution 182
F. Expenses of the Issue 182

 

 




 

  

​​
Item 10     Additional Information 183
A. Share Capital 183
B. Memorandum and Articles of Association 183
C. Material Contracts 183
D. Exchange Controls 183
E. Taxation 183
F. Dividends and Paying Agents 195
G. Statement by Experts 195
H. Documents on Display 195
I. Subsidiary Information 195
Item 11     Quantitative and Qualitative Disclosures About Market Risk 195
Item 12     Description of Securities Other than Equity Securities 198
A. Debt Securities 198
B. Warrants and Rights 198
C. Other Securities 198
D. American Depositary Shares 198
PART II 201
Item 13      Defaults, Dividend Arrearages and Delinquencies 201
Item 14     Material Modifications to the Rights of Security Holders and Use of Proceeds 201
Item 15     Controls and Procedures 201
Item 16     Reserved 202
Item 16A    Audit Committee Financial Expert 202
Item 16B     Code of Ethics 202
Item 16C     Principal Accountant Fees and Services 202
Item 16D     Exemptions from the Listing Standards for Audit Committees 203
Item 16E     Purchases of Equity Securities by the Issuer and Affiliated Purchasers 203
Item 16F     Change in Registrant’s Certifying Accountant 203
Item 16G     Corporate Governance 203
Item 16H      Mine Safety Disclosure 204
PART III 205
Item 17      Financial Statements 205
Item 18      Financial Statements 205
Item 19      Exhibits 205
EXHIBIT INDEX #
SIGNATURES #

 







 

Unless otherwise indicated or unless the context requires otherwise, “GLPG,” “the company,” “our company,” “we,” “us,” and “our” refer to Galapagos NV and its consolidated subsidiaries.

 

We own various trademark registrations and applications, and unregistered trademarks, including GALAPAGOS and our corporate logo. All other trade names, trademarks and service marks referred to in this annual report on Form 20‑F, or this annual report, are the property of their respective owners. Trade names, trademarks and service marks of other companies appearing in this annual report are the property of their respective holders. Solely for convenience, the trademarks and trade names in this annual report may be referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

 

Our audited consolidated financial statements have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB. Our consolidated financial statements are presented in euros. All references in this annual report to “$,” “US$,” “U.S.$,” “U.S. dollars,” “dollars,” and “USD” mean U.S. dollars and all references to “€” and “euros” mean euros, unless otherwise noted. Throughout this annual report, references to “ADSs” mean American Depositary Shares or ordinary shares represented by American Depositary Shares, as the case may be.

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This annual report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are based on our management’s beliefs and assumptions and on information currently available to our management. All statements other than present and historical facts and conditions contained in this annual report, including statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking statements. When used in this annual report, the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions identify forward-looking statements. Forward-looking statements include, but are not limited to, statements about:



· the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs;

· our ability to advance product candidates into, and successfully complete, clinical trials;

·
our reliance on the success of our product candidate filgotinib and certain other product candidates;

·
the timing or likelihood of regulatory filings and approvals;

·
our ability to develop sales and marketing capabilities;

·
the commercialization of our product candidates, if approved;

·
the pricing and reimbursement of our product candidates, if approved;

·
the implementation of our business model, strategic plans for our business, product candidates and technology;

·
the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

·
our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties;






· cost associated with enforcing or defending intellectual property infringement, misappropriation or violation; product liability; and other claims;

·
regulatory development in the United States, Europe, and other jurisdictions;

·
estimates of our expenses, future revenues, capital requirements and our needs for additional financing;

·
the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements;

·
our ability to maintain and establish collaborations or obtain additional grant funding;

· the rate and degree of market acceptance of our product candidates if approved by regulatory authorities;

·
our financial performance;

·
developments relating to our competitors and our industry, including competing therapies;

·
our ability to effectively manage and anticipate growth;

· our ability to attract and retain qualified employees and key personnel;

·
statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance; and

·
other risks and uncertainties, including those listed in the section of this annual report titled “Item 3.D.—Risk Factors.”

 

You should refer to the section of this annual report titled “Item 3.D.—Risk Factors” for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this annual report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Further, we cannot assess the impact of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statement.

 

You should read this annual report and the documents that we reference in this annual report and have filed as exhibits to this annual report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. In light of the significant risks and uncertainties to which our forward-looking statements are subject, you should not place undue reliance on or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. We discuss many of these risks in greater detail in this annual report. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

 

This annual report contains market data and industry forecasts that were obtained from third parties and industry publications. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified any third-party information. While we believe the market position, market opportunity and market size information included in this annual report is generally reliable, such information is inherently imprecise.

 

Please see the Glossary of Terms at the end of Item 4 for definitions of scientific and other terms used in this annual report.

 

 

Summary of risk factors

We are heavily dependent upon our global R&D collaboration with Gilead and the amendment of our arrangement with Gilead for the commercialization and development of  filgotinib including Gilead’s recruitment in the Phase 3 trial in Crohn’s disease. There can be no assurance that these arrangements will deliver the benefits we expect, including but not limited to the payment of potential future milestones, opt-in and/or royalty payments by Gilead.


The transition of European rights to filgotinib from Gilead to us will be a significant undertaking that may require additional substantial financial and managerial resources, and we may not be successful.


We have no historical product revenues, which makes it difficult to assess our future prospects and financial results.


We have limited sales and distribution experience and are currently building a marketing and sales organization. We expect to continue to invest significant financial and management resources to continue to build these capabilities and to establish a European commercial infrastructure. To the extent any of our product candidates for which we maintain commercial rights is approved for marketing, if we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to market and sell any product candidates effectively, or generate product revenues.


The marketing and sale of filgotinib or future approved products may be unsuccessful or less successful than anticipated. We are heavily dependent on the success of filgotinib, which is approved for the treatment of rheumatoid arthritis in Europe and Japan and marketed under the brand name Jyseleca, and under regulatory review in the European Union for the treatment of ulcerative colitis.


We are also dependent on the success of our other clinical-stage product candidates, such as our idiopathic pulmonary fibrosis candidates (GLPG1205 and GLPG4716 and other candidates), and our inflammation candidates/trials (such as GLPG3970, GLPG3667 GLPG3121, and GLPG4399, and the MANTA/MANTA RAy trials with filgotinib). We cannot give any assurance that any product candidate will successfully complete clinical trials or receive regulatory approval, which is necessary before it can be commercialized.


Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials as well as data from any interim analysis of ongoing clinical trials may not be predictive of future trial results or approved label for clinical use. Clinical failure can occur at any stage of clinical development.


Due to our limited resources and access to capital in the past, we have decided to prioritize development of certain product candidates and may have forgone the opportunity to capitalize on product candidates or indications that may ultimately have been more profitable or for which there was a greater likelihood of success.


We may not be successful in our efforts to use and expand our novel, proprietary target discovery platform to build a pipeline of product candidates.


The regulatory approval processes of the FDA, the EMA, the MHLW, and other comparable regulatory authorities are lengthy, time consuming and inherently unpredictable which may affect the commercial viability of our products in development. If we are unable ultimately to obtain regulatory approval for our product candidates, our business will be substantially harmed.


In connection with our global clinical trials, local regulatory authorities may have differing perspectives on clinical protocols and safety parameters, which impacts the manner in which we conduct these global clinical trials and could negatively impact our chances for obtaining regulatory approvals or marketing authorization in these jurisdictions, or for obtaining the requested label or dosage for our product candidates, if regulatory approvals or marketing authorizations are obtained.


Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.


Our future clinical trials or those of any of our collaborators may reveal significant adverse events not seen in our preclinical studies or earlier clinical trials and result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.



Coverage and reimbursement decisions by third-party payers may have an adverse effect on pricing and market acceptance.


Legislative and regulatory activity may exert downward pressure on potential pricing and reimbursement for any of our product candidates, if approved, that could materially affect the opportunity to commercialize.


We face significant competition for our drug discovery and development efforts, and if we do not compete effectively, our commercial opportunities will be reduced or eliminated.

 

Our ability to compete may decline if we do not adequately protect our proprietary rights.

 

Our business, results of operations and future growth prospects could be materially and adversely affected by the COVID-19 pandemic.

 

The market price of the ADSs could be subject to wide fluctuations.

 

We may be at an increased risk of securities class action litigation.





 

 

 

Our audited consolidated financial statements have been prepared in accordance with IFRS, as issued by the IASB. We derived the selected statements of consolidated operations data, selected statements of consolidated financial position and selected statements of consolidated cash flows, each as of and for the years ended December 31, 2020, 2019 and 2018 from the audited consolidated financial statements, which are included herein. We derived the selected statements of consolidated operations data, selected statements of consolidated financial position and selected statements of consolidated cash flows, each as of and for the years ended December 2017 and 2016 from our audited consolidated financial statements, which are not included herein.  

 

This data should be read together with, and is qualified in its entirety by reference to, “Item 5—Operating and financial review and prospects” as well as our financial statements and notes thereto appearing elsewhere in this annual report. Our historical results are not necessarily indicative of the results to be expected in the future.  

 

Consolidated statement of operations:

 

 

Year ended December 31,

 

    

2020

    

2019 (*)

    

2018 (*)

    

2017

    

2016

 

 

 

(Euro, in thousands, except per share data)

Revenues

 

478,053 

 

834,901 

 

278,666 

 

127,087 

 

129,519 

Other income

 

 

52,207 

 

 

50,896 

 

 

29,000 

 

 

28,830 

 

 

22,093 

Total revenues and other income

 

 

530,260 

 

 

885,797 

 

 

307,666 

 

 

155,918 

 

 

151,612 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

 

(523,667)

 

 

(420,090)

 

 

(316,222)

 

 

(218,502)

 

 

(139,573)

Sales and marketing expenses

 

 

(66,468)

 

 

(24,577)

 

 

(4,146)

 

 

(2,803)

 

 

(1,785)

General and administrative expenses

 

 

(118,757)

 

 

(72,382)

 

 

(34,377)

 

 

(24,415)

 

 

(21,744)

Total operating expenses

 

 

(708,892)

 

 

(517,049)

 

 

(354,746)

 

 

(245,720)

 

 

(163,103)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income/loss (-)

 

 

(178,632)

 

 

368,748 

 

 

(47,080)

 

 

(89,802)

 

 

(11,491)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Fair value re-measurement of share subscription agreement and warrants

 

 

3,034 

 

 

(181,644)

 

 

— 

 

 

— 

 

 

57,479 

Other financial income

 

 

18,667 

 

 

21,389 

 

 

18,264 

 

 

4,877 

 

 

9,950 

Other financial expenses

 

 

(152,844)

 

 

(59,968)

 

 

(2,602)

 

 

(30,582)

 

 

(1,692)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income/loss (-) before tax

 

 

(309,775)

 

 

148,525 

 

 

(31,417)

 

 

(115,507)

 

 

54,246 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income taxes

 

 

(1,226)

 

 

165 

 

 

(822)

 

 

(198)

 

 

(235)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income/loss (-) from continuing operations

 

 

(311,001) 

 

 

148,689 

 

 

(32,240)

 

 

(115,704)

 

 

54,012 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income from discontinued operations, net of tax

 

 

5,565  

 

 

1,156

 

 

2,981 

 

 

 

 

 

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income/loss (-)

 

(305,436)

 

149,845 

 

(29,259)

 

(115,704)

 

54,012 

Net income/loss (-) attributable to:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Owners of the parent

 

 

(305,436)

 

 

149,845 

 

 

(29,259)

 

 

(115,704)

 

 

54,012 

Basic income/loss (-) per share

 

(4.69)

 

2.60 

 

(0.56)

 

(2.34)

 

1.18 

Diluted income/loss (-) per share

 

(4.69)

 

2.49 

 

(0.56)

 

(2.34)

 

1.14 

Basic income/loss (-) per share from continuing operations

 

(4.78)

 

2.58 

 

(0.62)

 

(2.34)

 

1.18 

Diluted income/loss (-) per share from continuing operations

 

(4.78)

 

2.47 

 

(0.62)

 

(2.34)

 

1.14 

Weighted average number of shares - Basic (in '000 shares)

 

 

65,075

 

 

57,614 

 

 

52,113 

 

 

49,479 

 

 

45,696 

Weighted average number of shares - Diluted (in '000 shares)

 

 

65,075

 

 

60,113 

 

 

52,113 

 

 

49,479 

 

 

47,308 

















(*) The 2019 and 2018 comparatives have been restated to consider the impact of classifiying the Fidelta business as discontinued opearations in 2020.

 

 

Condensed consolidated statement of financial position:


 

 

December 31,

 

    

2020

    

2019

    

2018

    

2017

    

2016

 

 

 

(Euro, in thousands)

Current financial investments

 

3,026,278

 

3,919,216 

 

— 

 

— 

 

— 

Cash and cash equivalents

 

 

2,135,187

 

 

1,861,616 

 

 

1,290,796 

 

 

1,151,211 

 

 

973,241 

Cash and cash equivalents classified as assets held for sale

 

 

7,884

 

 

— 

 

 

— 

 

 

— 

 

 

— 

Total assets

 

 

5,717,731 

 

 

6,068,609 

 

 

1,439,496 

 

 

1,286,274 

 

 

1,083,338 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share capital

 

 

291,312

 

 

287,282 

 

 

236,540 

 

 

233,414 

 

 

223,928 

Share premium account

 

 

2,727,840

 

 

2,703,583 

 

 

1,277,780 

 

 

993,025 

 

 

649,135 

Total equity

 

 

2,670,355

 

 

2,875,658 

 

 

1,214,249 

 

 

1,011,983 

 

 

758,701 

Total non-current liabilities

 

 

2,412,101

 

 

2,621,158 

 

 

5,342 

 

 

102,592 

 

 

220,846 

Total current liabilities

 

 

635,274

 

 

571,793 

 

 

219,905 

 

 

171,699 

 

 

103,791 

Total liabilities

 

 

3,047,375

 

 

3,192,951 

 

 

225,247 

 

 

274,291 

 

 

324,637 

Total liabilities and equity

 

5,717,731

 

6,068,609 

 

1,439,496 

 

1,286,274 

 

1,083,338 

 

Condensed consolidated statement of cash flows:


 

    

2020

    

2019

    

2018

    

2017

    

2016

 

 

(Euro, in thousands)

Cash and cash equivalents at beginning of the period

 

1,861,616 

 

1,290,796 

 

1,151,211 

 

973,241 

 

340,314 

Net cash flows generated/used (-) in operating activities

 

 

(427,336)

 

 

3,208,617 

 

 

(142,466)

 

 

(147,030)

 

 

239,403 

Net cash flows generated/used (-) in investing activities

 

 

757,288

 

 

(3,764,660)

 

 

(15,914)

 

 

(549)

 

 

(7,287)

Net cash flows generated in financing activities

 

 

22,040

 

 

1,335,751 

 

 

287,876

 

 

353,357 

 

 

395,996 

Transfer to current financial investments

 

 

— 

 

 

(198,922)

 

 

— 

 

 

— 

 

 

— 

Effect of exchange rate differences on cash and cash equivalents

 

 

(70,539)

 

 

(9,966)

 

 

10,089

 

 

(27,808)

 

 

4,816 

Cash and cash equivalents at end of the period

 

2,143,071 

 

1,861,616 

 

1,290,796 

 

1,151,211 

 

973,241 

 

 

 

 

December 31,

 

 

2020

    

2019

    

2018

    

2017

    

2016

 

 

 

(Euro, in thousands)

Current financial investments  

 

3,026,278

 

3,919,216 

 

— 

 

— 

 

— 

Cash and cash equivalents from continuing operations

 

 

2,135,187

 

 

1,861,616 

 

 

1,290,796 

 

 

1,151,211 

 

 

973,241 

Cash and cash equivalents classified as assets held for sale

 

 

7,884

 

 

— 

 

 

— 

 

 

— 

 

 

— 

Current financial investments and cash and cash equivalents

 

5,169,349 

 

5,780,832 

 

1,290,796